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GENERAL INTRODUCTION 
CHAPTERl 
GENERAL INTRODUCTION 
1.1 INTRODUCTION 
The incidence of carcinoma of the bladder is higher in industrialized 
countries than in underdeveloped regions such as Asia and Africa (excluding 
areas where schistosomiasis is endemic I). 
In the Netherlands bladder cancer ranges fourth in the order of frequency in 
the occurrence of tumours in males (40.7 per 100000 person-years, stand-
ardized to the European standard population). In females bladder cancer is 
less frequent (twelfth most frequent; 8.5 per 100000 person-years). The male-
female ratio is 4.8 to 1 (non-infiltrating and infiltrating bladder cancer 
together).2 In other countries, including the USA, the male predominance is 
less pronounced.3 
Bladder cancer typically affects older persons. Its peak incidence occurs in the 
6th and 7th decades of life. Although the disease may develop in patients 
under 45 years of age, only approximately 2 percent of the cases occur in this 
age group. 
The disease is at least in part attributable to exposure to carcinogens. 
Arylamines, used in various industrial settings, have been cited as agents 
involved in the development of bladder cancer.4-7 Other factors include 
viruses, radiation and coffee intake. The most important factor however 
appears to be cigarette smoking. 8, 9 The incidence of bladder cancer in 
cigarette smokers is two to three times higher than in non smokers. 
1.2 HISTOPATHOLOGICAL FACTORS 
In the management of bladder cancer the "classic" prognostic parameters 
pathological stage and grade still play an important role next to clinical 
factors like clinical staging and cystoscopy. These two pathological factors 
have been subject to our investigations and are introduced under separate 
subheadings. 
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1.2.1 Histopathological staging 
In the evaluation of patients with bladder cancer the determination of tumour 
stage has become an essential step. Bladder cancer stage is an important 
criterium for the clinician in planning treatment, predicts eventual outcome 
and helps to standardize patient groups which makes studies from different 
investigators more or less comparable. Current methods of staging rely 
primarily on bimanual palpation, cystoscopy and histopathological examina-
tion. The most widely accepted staging system is the TNM classification of 
malignant tumours.JO In this staging system the distinction is made between 
non-papillary carcinoma in situ (Tis) and papillary non-infiltrating tumours 
(Ta). T1 tumours invade in the lamina propria. T2, T3 and T4 tumours show 
invasion of respectively the superficial parts of the muscularis, deep in-
tramuscular and contiguous organs. In the USA the Marshall modification of 
the Jewett and Strong systemll, 12 is also in use. Although varying in details, 
both recognise the following features of urothelial carcinoma: (1) tumour 
behaviour is directly related to the depth of invasion into the bladder wall, (2) 
muscular invasion is the most accessible factor in determining tumour ag-
gressiveness, (3) invasion in perivesical structures and metastases to 
lymphnodes or distant organs are grave prognostic signs, (4) non-invasive 
papillary lesions have a good prognosis. A disadvantage of the Jewett and 
Strong system of staging is that no difference is made between flat carcinomas 
in situ and non invasive papillary tumours, which are both classified as stage 
0. 
Unfortunately staging also has its problems.13 It is sometimes difficult to 
assess infiltration in superficial tumours. The pathologist's interpretation of 
infiltration in Ta and T1 tumours is sometimes inconsistent and not always 
reproducible. To assess the exact infiltration depth of tumours an adequate 
biopsy is necessary, containing a part of the muscularis of the bladder wall. 
1.2.2 Histopathological grading 
The gross appearance of Transitional Cell Carcinoma (TCC) is extremely 
varied, ranging from delicately papillary to polypoid to flat and/ or ulcerated. 
The growth pattern of TCC may be purely papillar, purely solid or both 
papillary and solid. Although gross examination is of obvious importance in 
guiding sampling, the most important information is obtained from his-
topathological examination. Several systems have been developed for the 
histopathological grading of carcinoma of the urinary bladder, 14-19 but most 
of them did not gain wide acceptance. The most commonly used system is the 
grading system proposed by the American Bladder Tumor Registry and the 
World Health Organisation (WH0).16 The WHO recommends classification 
of epithelial tumours into four primary histological types: TCC, squamous 
cell carcinoma, adenocarcinoma and undifferentiated carcinoma. TCC con-
stitute about 92 percent of the epithelial tumours, squamous cell carcinomas 
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6 to 7 percent, adenocarcinomas 0.5 to 2 percent and undifferentiated car-
cinomas less than 1 percent. Up to 20 percent of TCC contain areas of 
squamous cell differentiation, whereas glandular differentiation is present in 
7 percent. 
A major problem in grading is the high inter- and intra-observer variability. 
In most systems a sharp distinction between different grades cannot be ob-
tained, mainly because of the many variables used. Although the WHO 
grading system is the most accepted system of grading, the problem of 
reproducibility also has been demonstrated.20, 21 To compare the results of 
different studies using histopathological grading as a prognostic factor, grad-
ing systems should be available with high reproducibility. As long as this 
goal has not been achieved the results of histopathological grading as a 
prognostic factor should be interpreted prudently. 
1.3 OBJECTIVE PROGNOSTIC PARAMETERS 
Because histopathological factors have their problems in reproducibility, 
there is a need for objective other prognostic parameters. To reduce the grey 
area between low-grade malignant tumours and high-grade malignant TCC 
all efforts are aimed at creating a clear dichotomy between these extremes. 
The problem here, however, is of a biological nature, because low- and 
high-grade tumours are not separate and distinct entities, but extremes on a 
continuous scale. A number of possible prognostic factors have been analysed 
in the past. Already in the seventies cytogenetic factors22 and bloodgroup 
antigen (BGA) 23 deletion were reported to have predictive value with respect 
to recurrence and progression. Later reports have contradicted the value of 
BGA deletion as prognostic factor.24 Biochemical factors have been reported 
as being of possible clinical value in TCC like the autocrine motility factor, 25 
epidermal growth factor, 26 tissue polypeptide antigen27 and transferrin 
receptor.28 PCNA29 and Ki6730 are used as proliferation markers with prog-
nostic value. Further study is necessary to fully validate the additional value 
of all these factors in the management of TCC. 
The factors with possible prognostic value which have been subject to our 
investigations are introduced under separate headings. 
1.4 BASEMENT MEMBRANES 
In all epithelial tissues basement membranes (BM) form the boundary be-
tween the epithelial compartment and adjacent stroma. BM are not static 
structures but are continuously catabolized and redeposited.31 BM defects in 
neoplasm are caused by an imbalance between breakdown and production. 
Transition from in situ carcinoma to invasive carcinoma implies BM 
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dominance of breakdown and the possibility of passage of tumour cells 
through the interrupted BM.32, 33 Visualisation of the BM could be helpful in 
assessing minimal infiltration.33-35 Early attempts by Ozzello36 to outline BM 
in breast cancer by PAS staining were frustrated by the occurrence of PAS 
reactive glycoproteins not only in BM but also in interstitial connective tissue. 
Electron microscopy appeared to be suitable for the study of BM, 37,38 but this 
technique is too complicated and too expensive for routine application. The 
immunohistochemical localization of BM components has greatly expanded 
the possibilities to study the role of the BM in cancer invasion.32-35, 39-41 BM 
deposition in cancer can also be regarded as an indicator of differentiation of 
a particular neoplasm.40 
There are only a few reports concerning BM staining in bladder car-
cinomas.42, 43 In one study a significant correlation was seen between BM 
continuity or discontinuity and progression.42 In the other study bladder 
cancer patients with intact BM showed longer survival than patients with BM 
discontinuities.43 
1.5 NUCLEAR MORPHOMETRY 
The value of nuclear morphometry as a technique to discriminate between 
different histological grades in TCC has been investigated in several 
studies.44-53 Some of the studies reported on the reproducibility of the 
methods, 21,49 which is an essential requirement for broad application of such 
a method for prognostic purposes. Previous morphometric studies varied in 
their methodology. The methods of nuclear sampling varied as well the 
number of measured nuclei. ln their report on the prognostic significance of 
morphometry in TCC Ooms et aJ.46 described a method in which nuclei are 
measured in areas of nuclear crowding and in areas with the most 
pronounced nuclear enlargement. In such areas nuclear and cellular size were 
measured in 20 cells. They found that nuclear size was larger and nucleus-cell 
ratio smaller in non survivors. 
Bjelkenkrantz et al. found an increase in nuclear size with grade. Their 
method of measurement was not described in detaiJ.44 Later, Ooms et al. 
described a new method of morphometric grading by measuring superficial 
and basal layer nuclei and the largest nuclei found in a TCC.47 By plotting the 
mean nuclear area of the largest nuclei against the mean area of basal cell 
nuclei or the mean area of superficial cell nuclei, they could divide ICC in 
low, high and intermediate grades. The clinical value of these grades was not 
evaluated. A similar observation was reported by Monteroni et aJ.48 but using 
different parameters than Ooms et aL.47Jn several studies grade II ICC could 
be separated by morphometry into two groups of patients, with different 
clinical behaviour.45, 50 Some studies analysed the clinical value of mor-
phometry in TCC in comparison with classic parameters in relative small 
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groups of patients.S0-53 Blomjous et al. studied different methods of mor-
phometric grading and found that selective measurement of the ten largest 
nuclei, after selection of the most atypical area of the TCC, gave the best 
results.21 
1.6 DNAANALYSIS 
Deoxyribonucleic acid (DNA) ploidy analysis by flow cytometry (FCM) has 
steadily gained acceptance in recent years as a diagnostic and prognostic tool 
in the management of patients with TCC.51, 54-60 Aneuploidy, as determined 
by FCM, appeared to be a parameter which can predict which tumours will 
progress.56, 58-60 However, tumours with only a few cells with high DNA 
content against a background of abundant diploid tumour cells, might be 
classified as diploid by FCM and this approach therefore lacks in sensitivity. 
Image or static cytometry offers an alternative approach to DNA ploidy 
analysis.61-70 By means of a video camera and computer, digitized images of 
cells are acquired from stained slides, viewed under a microscope. This 
technique permits DNA measurements to be performed under visual control. 
It has been shown by several authors that valuable prognostic information 
can be obtained from the nuclear DNA distribution pattern using this ap-
proach. In early, manually performed, image cytometric studies on imprints 
of fresh tumour tissue of TCC a correlation was found between DNA values 
and survival in univariate analyses.61-65 Bocking et al. showed with the aid of 
multivariate analysis using age, tumour stage and tumour grade as co-
variates, that DNA grading was the only factor which contributed significant-
ly to predicting survival.64 Stockle et a!. also used automated DNA image 
cytometry and derived two parameters from the histograms (DNA ploidy 
and the number of cells above SC) which correlated well with survival in 
patients with stage T1 to T4 TCC.69 
1.7 CYTOGENETIC ANALYSIS 
DNA content of tumour cells can be rapidly and objectively estimated by flow 
and image cytometry.48, 51, 54-70 However these techniques only allow es-
timation of the total DNA content in large cell populations, but no specific 
information about chromosomal aberrations can be obtained. Karyotyping of 
tumours allows more precise determination of numerical and/ or structural 
chromosome defects. One of the first reports on chromosome abnormalities in 
human tumours was published in 1960 by Nowell and Hungerford when they 
described an abnormal small chromosome, the so called Philadelphia 
chromosome, in patients with chronic myelogenous leukaemia?l Numerous 
chromosomal abnormalities in human cancer have been reported since 
15 
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then?2-75 With the introduction of banding techniques about 1970, 76 it 
became relatively easy to recognize the individual chromosomes and their 
structural abnormalities, at least when sufficient metaphases of adequate 
quality were obtained. 
The first study on chromosomes in TCC was published in 1965 by Shigemat-
su.77 He found a relation between the number of chromosomes and the 
histological type of TCC. In a study of Spooner and Cooper an increase in 
modal number of chromosomes was associated with histological grade and 
stage in TCC.22 These authors found that well and moderately well differen-
tiated tumours fall within the diploid range (42 to 49 chromosomes), whereas 
the majority of poorly differentiated cancers show a widespread distribution 
of chromosome number. In some studies a large number of structural abnor-
malities was found, including marker chromosomes, especially in poorly 
differentiated and invasive tumours?S-81 Low-stage and low-grade car-
cinomas of the bladder were nearly always diploid or near diploid (42 to 49 
chromosomes), although a few marker chromosomes have been observed?9, 
80 Pauwels et al. reported on modal chromosome number and range in 
relation to progression and recurrence and found that marker chromosomes 
had no predictive value.82 The range of chromosome number appeared to be 
the best predictor for invasion. Smeets et al. found that monosomy of 
chromosome 9 is a frequent aberration in diploid TCC.83 Karyotyping is only 
possible when fresh tumour tissue is available. Especially in tumours with a 
low number of mitoses it is sometimes difficult to obtain sufficient 
meta phases. 
In situ hybridization (ISH) using a number of chromosome specific probes 
allows the detection of numerical chromosome aberrations in the interphase 
nucleus.84-87 Most studies on ISH methods have dealt with the application on 
fresh TCC tissues.87-90 A limited number of studies describe the application 
of this technique on routinely processed paraffin materiaJ.91, 92 
This technique provides valid information about numerical chromosome 
aberrations in bladder cancer. This method offers the possibility to perform 
retrospective studies using paraffin blocks. Hybridization with different 
probes on the same tumour areas in parallel sections or double target ISH 
enables to study chromosome ratios and therefore the loss of some specific 
chromosomes.91 
1.8 AIM OF THE STUDY 
The main purpose of the studies reported in this thesis has been to determine 
the extent to which the behaviour of TCC can be predicted by histopathologi-
cal and biological characteristics. The potential additional prognostic value of 
these factors was evaluated by combining them with other prognostic factors 
in multivariate analysis. In chapter 2 a two grade system of histological 
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grading .. using simple histological criteria, is proposed. The interobserver 
variability of the WHO grading system and the two grade system is tested. 
The extent to which patient survival and progression free survival correlated 
with the two grade system, is evaluated. The additional value of grading is 
tested by combining it with other prognostic factors such as stage, age and 
mitotic index in multivariate analysis. In chapter 3 BM expression in TCC is 
described in an attempt to evaluate its use for the histopathological identifica-
tion of microinvasion. Furthermore the usefulness of BM staining for the 
prediction of the clinical behaviour of TCC is assessed in comparison with 
grading, staging and ploidy. In chapter 4 the use of a two grade morphometri-
cal grading system for prediction of the clinical behaviour of TCC is 
described. Also the heterogeneity in the WHO grade II tumours is evaluated 
using morphometry. In chapter 5 a study is reported in which it is determined 
whether image cytometry can provide useful parameters which can be used 
in the prediction of TCC behaviour. Special attention is given to the potential 
value of rare incidents, e.g. occasional cells with a very high DNA content. In 
chapter 6 a study is described concerning numerical chromosome aberrations 
in TCC as assessed by counting chromosomes in metaphase spreads. The 
modal number of chromosomes and the chromosomal range are used as 
potential prognostic factors in comparison with histological parameters. In 
chapter 7 "classical" metaphase chromosome counting is compared with 
interphase cytogenetics, especially in tumours having diploid and hyper-
diploid DNA content. In chapter 8 The findings of these studies are discussed 
and general conclusions are drawn. 
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2.1 ABSTRACT 
For histological grading of transitional cell carcinoma (TCC) of the urinary 
bladder, most pathologists prefer to use the three-grade system as proposed 
by the American Bladder Tumor Registry and the World Health Organization 
(WHO). However, interobserver agreement appears to be unacceptably low. 
We developed a simplified grading system in which only low-grade and 
high-grade tumours are distinguished and report on its reproducibility and 
predictive value for survival and progression. Reproducibility was good to 
excellent with a group Kappa value of 0.78. 
The effect on survival and progression-free interval was measured in a group 
of 311 patients with bladder tumours. The survival of patients with low-grade 
tumours was significantly better than that of patients with high-grade 
tumours (P < 0.0001). The progression-free interval was also significantly 
longer in patients with low-grade tumours than in patients with high-grade 
tumours (P = 0.0032). Combining low-high grading, histological stage, 
mitotic index, and age, histological stage appeared to be the most important 
parameter in predicting survival and progression. 
A reproducible and discriminating system such as our low-high grade sys-
tem, is an important prognostic factor when stage cannot be established with 
certainty. 
2.2 INTRODUCTION 
The urinary bladder is the site of origin of a variety of benign and malignant 
neoplasms. The most important group of tumours consists of epithelial 
tumours of the transitional cell type. To provide a rational basis for follow-up 
and treatment, a generally accepted system of clinico-pathological classifica-
tion is essential. The most wide! y accepted staging system is the TNM clas-
sification) For histopathological classification the WHO system is generally 
in use.2 In the WHO grading system a sharp demarcation between different 
grades cannot be attained. This results in considerable interobserver 
variability, and therefore poor agreement between diagnoses made by dif-
ferent pathologists_3, 4 Unfortunately, staging has its problems as well. The 
pathologist's interpretation of infiltration in theTa and T1 group of tumours 
may be inconsistent and not reproducible.S To assess the exact infiltration 
depth of tumours an adequate biopsy should be obtained, containing all 
layers of the bladder wall. Several efforts have been made to improve existing 
or to develop new grading systems, 6-12 but these have not gained wide 
acceptance. In some studies stage has proved to be the most discriminating 
variable to predict clinical outcome.l2-14 However in another study histologi-
cal grading was claimed to be the best predictor of clinical outcome.13 The 
purpose of the present study was to determine the extent to which the 
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biological potential of transitional cell neoplasms can be predicted by his-
tological grading of the primary tumour in a two grade system using simple 
histological criteria. We also evaluated the additional value of grading when 
combined with other prognostic factors. The interobserver variability of the 
WHO grading and the two grade system was tested. 
2.3 MATERIALS AND METHODS 
The study included 311 patients with newly diagnosed bladder carcinomas 
(only TCC) seen at the St. Maartens Hospital, Venia (community hospital 
serving the Northern Limburg area) between January 1979 and June 1990. 
Two hundred fifty six patients (82.3%) were male and fifty five (17.7%) were 
female. Age ranged from 17 to 92 years with a mean of 66 years. All patients 
were treated by transurethral resection (TUR) of the tumour. Seventy four of 
them received additional adjuvant intravesical therapy. Sixty seven patients 
were treated additionally by radiotherapy, cystectomy or both. 
Clinicopathological information and TUR specimen were collected prospec-
tively. Staging was carried out according to the TNM system.l 
The median follow-up was 38 months, with a maximum of 150 months (mean 
46.2 months). Follow-up examinations were conducted at least semi-annually 
and included cystoscopy and urinary cytology. As follow-up criteria survival 
and progression-free interval were chosen. Progression, defined as increase in 
stage or death due to tumour, was assessed histologically by pathologists 
without knowledge of previous diagnostic information and clinical data.lf a 
patient was lost to follow-up, survival was assessed by contacting municipal 
population registries. 
2.3.1 Clinico-pathological methods 
All tumours were classified according to a simplified method of grading. In 
this grading system only two grades are distinguished: low-grade and high-
grade. The grading criteria are summarized in table 1 and illustrated in figure 
1, We encountered some tumours with very small areas of abnormal polariza-
tion and moderate pleomorphism. These were mostly papillary tumours. We 
included them in the group of the low-grade tumours. Carcinoma in situ, 
pure squamous cell carcinoma, pure adenocarcinoma and undifferentiated 
carcinoma were not evaluated in this study. 
Furthermore, we estimated the mitotic index (counts/10hpf), using the count-
ing method as described by van Diest et aJ..lS We counted 10 fields using a 
xlO ocular and a x40 objective with a numerical aperture of 0.75 and a field 
width of 450 J.Lm. The criteria described by Baak were used to identify mitotic 
figures.l6 
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Figure 1. Low-grade TCC (A and B) with thickening of the epithelium, normal polarity of nuclei 
and none or slight pleomorphism (x250). High-grade TCC (C and D) with loss of polarity of 
nuclei and moderate to prominent pleomorphism (x250). 
2.3.2 Statistical analysis 
The following prognostic factors were included in the analysis: low /high 
grading, T category (Stage Ta; Tl; T2 or more), mitotic index (less than 5 
mitoses/10 hpf; 5 or more mitoses/10 hpf), age (less than 70 years; 70 years or 
more), and sex. For each prognostic factor Kaplan Meier survival curves17 
were compared by means of the log rank test18 with regard to time interval to 
death and time interval to establishment of progression. A possible associa-
tion between various prognostic factors was analysed using the Pearson chi 
square test. 
26 
GRADING AND BLADDER CANCER 
Table 1. Grading criteria urothelial tumours 
Papilloma: a. Urothelium fewer than 7 layers in thickness. 
b. normal polarity of nuclei. 
c. No pleomorphism. 
Low-grade: a. Thickening of the urothe!ium (?:.71ayers) 
* b. Normal polarity of nuclei in 95% or more of the tumour. 
* c. None or only slight pleomorphism in 95% or more of the tumour. 
High-grade: a. Loss of polarization of the nuclei. 
b. Moderate or prominent pleomorphism. 
*rn contrast to the WHO grading system some areas of the tumour may show a loss of 
polarization of the nuclei and/ or moderate pleomorphism ( <5% of the tumour). 
For low /high grading the relative survival rate was calculated. The relative 
survival rate is the ratio of the observed survival rate in the group of patients 
to the expected survival rate in a group of people in the general population of 
the region, who are similar to the patients with respect to age, sex and 
calender time. Heterogeneity in withdrawal is taken into account. The 
regional mortality figures are derived from the Central Bureau of Statistics 
(CBS). We used the special computer programme of the Finnish Cancer 
Registry.19 
Furthermore, multivariate survival analyses were performed using Cox 
proportional hazards modeJ.20 In these models, low /high grading was in-
cluded together with the other above mentioned prognostic factors. The 
stepwise method was used to select the model, with use of the likelihood ratio 
test. A P-value of 0.05 was adopted as limit for entering and removing 
covariates. Of the prognostic factors, that contributed significantly to the 
model, the effect was calculated in terms of relative risk and the associated 
95% confidence interval. The statistical analyses were performed with the 
SAS statistical package (SAS Inst Inc, Cary, North Carolina, USA). 
2.3.3 Interobserver agreement 
For evaluation of the interobserver variation four pathologists, three without 
special expertise in urothelial tumours, examined biopsy specimens of 88 
consecutive cases of urothelial carcinoma from our files, without any 
knowledge of clinical outcome and prior histological grading. Both our 
simplified grading method and WHO system of grading2 were used. Kappa 
statistics21 were used to evaluate the degree of agreement between pairs of 
pathologists and among the group of pathologists. 
27 
GRADING AND BLADDER CANCER 
Kappa was evaluated as described by Fleiss: 22 in general, Kappa values 
below 0.40 indicate poor agreement, kappa values between 0.40 and 0.75 
indicate fair to good agreement and Kappa values above 0.75 indicate excel-
lent agreement. 
2.4 RESULTS 
2.4.1 Prognostic factors 
The frequency distribution for low /high grading, stage and mitotic index is 
shown in table 2. Strong association was seen between low /high grades and 
stage (P < 0.0001), and mitotic index (P < 0.0001). 
Table 2. Association between low-high grading, histopathological stage and mitotic index. 
Grading 
LOW HIGH Total 
Stage Ta 111 43 154 
Tl 4 98 102 
T2+ 0 55 55 
Mitotic index 55 107 60 167 
>5 8 136 144 
Total 115 196 311 
2.4.2 Survival 
For low /high grading we found a significant difference in survival (P < 
0.0001) (fig. 2). Of the 115 patients with low-grade tumours, 2 died of tumour 
related disease and 29 died of (probably) unrelated causes of death. Of the 196 
patients with high-grade tumours 45 died of tumour related disease and 70 
died of (probably) unrelated causes of death. The survival of patients with 
low-grade TCC was almost the same as the expected survival of people in the 
general population of the region resulting in a relative survival of almost 
hundred percent. In patients with high-grade tumours the survival is worse 
than the expected survival (fig. 3). 
Other strong predictors of survival were stage (P < 0.0001) (fig. 4) and mitotic 
index (P < 0.0001). 
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Figure 6. Progression-free survival according to tumour stage (T). I=Ta (n=154), 
II=Tl (n=102), ffi=T2 or more (n=55). 
5 year progression free survival: 1=89.9% (95% Cl, 84.1-95.4), 11=64.6% (95% Cl, 
54.2-74.9), ffi=34.9% (95% Cl, 20.7-49.3). 
In multivariate analysis, only stage (P < 0.0001) and age (P = 0.0012) were 
contributing significantly to the prediction of survival. 
2.4.3 Progression 
We found a significant association between low and high grades and progres-
sion-free interval (P < 0.0001) (fig. 5). Other strong predictors of progression 
were stage (P < 0.0001) (fig 6), and mitotic index (P < 0.0001) (fig 7). 
In the multivariate analysis stage again was the most important prognostic 
parameter in predicting progression (P < 0.0001) next to the mitotic index (P 
= 0.0005). The other variables did not show a significant independent predic-
tion. 
2.4.4 Superficial TCC 
For superficial tumours (TA+ Tl) the mitotic index appeared to be the most 
important parameter in predicting survival (P < 0.0001) and progression-free 
interval (P < 0.0001). However, when superficial TCC was divided into two 
separate groups of tumours, Ta and Tl, stage appeared to be an independent 
parameter in the prediction of survival (in multivariate analysis), while 
mitotic index lost its importance. Stage also appeared to be the best predictor 
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Figure 7. Progression-free survival according to mitotic index (MI). I= MI < 5 
(n=l67), II= MI;, 5 (n=l44). 5 year progression free survival: 1=89.8% (95% Cl, 
84.6-95.0), 11=51.6% (95% CI, 42.2-61.0). 
of progression in superficial tumours (P < 0.0001). Mitotic index is of border-
line significant importance in the prediction of progression (P = 0.0464). 
2.4.5 Interobserver agreement 
The frequency distribution of low /high grading performed by four 
pathologists is presented in table 3. Kappa values for agreement between 
pairs of pathologists with the low /high grading system ranged from 0.71 to 
0.85. The group kappa of the 4 pathologists was estimated at 0.78 (SE 0.05). 
With the WHO grading system kappa values ranged from 0.33 to 0.70 result-
ing in a group kappa was of 0.48 (SE 0.05). 
Table 3. lnterobserver agreement in low /high grading 
Grading 
low-grade 
high-grade 
Pathologist 
26 
62 
2 
31 
57 
3 
35 
53 
4 
29 
59 
Kappa values between pairs of pathologists ranged from 0.71 to 0.85. Group Kappa was 0.78 
(SE 0.05). 
32 
GRADING AND BLADDER CANCER 
2.5 DISCUSSION 
Several systems have been proposed for histopathological grading of TCC of 
the urinary bladder.2, 6-12 The most widely accepted system is the three grade 
WHO system.Z However the criteria for the different grades are considered to 
be rather vague, resulting in considerable interobserver variability.3· 4 Blom-
jous eta!. reported kappa values for agreement between pairs of pathologists, 
using the WHO grading system, ranging from 0.38 to 0.63.4 The same obser-
vation was made in our study. We found kappa values between pairs of 
observations, when using the WHO system, ranging from 0.33 to 0.70. Jordan 
et al. designed a detailed grading system, with many variables, in which 87% 
of TCC were classified as either low-grade (TCC-l) or high-grade (TCC-111).11 
Only 13% of cases fell into an intermediate category (TCC-II) and these 
closely followed the low-grade tumours with regard to survival and tumour 
progression. However, also these authors stated that inconsistency in the use 
of this system by different pathologists should be expected because of the 
many variables used. 
In the presently proposed grading system only three criteria were employed 
to discriminate between low and high grades: epithelial thickness, nuclear 
polarity and pleomorphism. 
Our working hypothesis was that the proposed low-high grading system 
would be reproducible, also when applied by pathologists without special 
expertise in urothelial tumours and would be informative with regard to 
clinical outcome. 
We found that this simplified method of grading indeed shows good agree-
ment between pathologists (group kappa = 0.78). This is mainly due to the 
simple criteria and the reduction in the number of categories. 
As to the prediction of clinical outcome we have shown that patients with 
low-grade tumours have significantly longer overall survival and a longer 
progression-free survival than patients with high-grade tumours. Patients 
with low-grade tumours have approximately the life expectancy of the 
general population in the region. Our material was also analysed for a num-
ber of additional prognostic factors. Stage and mitotic index were found to 
have significant correlation with overall survival and the progression-free 
survival (age correlated, as expected, significantly with survival only). 
The possible additional value of low-high grading in predicting clinical out-
come was evaluated in multivariate analyses using stage, mitotic index and 
age as co-variate. Our results indicate that of all these variables, stage is the 
most important independent prognostic parameter for overall survival and 
progression. Due to the strong correlation between low /high grading and 
stage, the simplified grading provided no significant additional independent 
value. Mitotic index was the only parameter providing independent addition-
al information concerning progression-free interval. 
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In conclusion, tumour stage remains the most important indicator for overall 
survival and tumour progression. The mitotic index provides important ad-
ditional information. The division of superficial TCC in Ta and T1 tumours is 
useful, because these tumours did show a different behaviour independent of 
other parameters. Grading, preferably performed using a reproducible and 
discriminating system such as our low-high grade system, is important when 
stage cannot be established with certainty. The WHO grading system is not 
reproducible and as such not suitable for comparing results of epidemiologi-
cal studies and results of therapy. 
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3.1 ABSTRACT 
Invasion of a carcinoma involves the degradation and penetration of the 
subepithelial basement membrane (BM). This phenomenon might be used for 
histopathological evaluation of neoplasms of the bladder. The authors 
studied the clinicopathological data and tissue specimens of 125 cases of 
urothelial carcinomas, collected prospectively. Penetration of the BM was 
evaluated by immunohistochemical staining of the BM components laminin 
and type IV collagen. The use of this parameter as a prognostic indicator in 
bladder cancer was assessed. The 5-year survival rate of patients having 
tumours with an interrupted or absent BM was significantly lower than that 
of patients having tumours with an intact BM. The rate of progression was 
greater in tumours with an interrupted or absent BM than in tumours with an 
intact BM. No association was found between BM status and recurrence. 
However, a significant correlation between tumour stage and BM staining 
was found. A correlation was also found between ploidy and BM staining, as 
well as between histological grade and BM staining pattern. 
When evaluating histological grade, stage, ploidy, age and BM score as 
prognostic parameters, the stage of bladder carcinomas turned out to be the 
most important factor in predicting the survival rate and the progression free 
survival. However, BM staining was found to be of value for early identifica-
tion of microinvasion and is as such helpful for correct staging of urothelial 
carcinomas. 
3.2 INTRODUCTION 
The rapidly increasing knowledge in molecular biology and the new pos-
sibilities of biotechnology have opened new opportunities for the develop-
ment of new approaches towards diagnosis and classification of neoplastic 
disease. Tumour invasion is an area that has benefitted remarkably from 
these developments. Invasive growth of a carcinoma is defined as the 
penetration of malignant neoplastic cells through a basement membrane 
(BM). ln this view the BM serves as an important structural barrier to progres-
sion of the neoplasm. To infiltrate and metastasize an epithelial neoplasm has 
to penetrate one or more BM layers. BM degrading proteases such as type IV 
collagenase play an important part in this process.l, 2 Recent studies indicate 
that BM are not static structures destined only for destruction, but they can 
also be deposited in tumour tissue. 
The study of BM morphologic features in invasive cancer is not new. Earlier 
attempts to outline BM in breast cancer by periodic acid-Schiff (PAS) staining 
were frustrated by the occurrence of PAS-reactive glycoproteins not only in 
BM but also in interstitial connective tissue. 3Immunohistochemical detection 
of BM components appears to be a more suitable approach towards the study 
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of invasive growth. Visualization of the BM by immunohistochemical techni-
ques with BM-specific antibodies is specific and provides very high resolu-
tion. This technique is reliable and reproducible and now forms one of the 
essential tools in the study of the role of the BM in neoplasia. Both laminin 
and type IV collagen have been used as markers of BM in turnours.4-7 
There are only a few reports published concerning BM staining in bladder 
carcinomas. B. 9 In one study a significant correlation was seen between BM 
continuity or discontinuity and progression (P = 0.036).8 In the other study 
bladder cancer patients with intact BM showed longer survival than patients 
with BM discontinuities (P < 0.001).9 We studied BM expression in bladder 
carcinomas to evaluate its use for the histopathological identification of 
microinvasion. Furthermore this study was performed to assess the useful-
ness of BM staining in comparison with grading, staging and ploidy for the 
prediction of the biological behaviour of bladder tumours. 
3.3 MATERIALS AND METHODS 
The Department of Urology of the St. Maartens Gasthuis (Venlo, the Nether-
lands) provides a regional service for the Northern Limburg area. All patients 
diagnosed with primary bladder carcinoma between january 1979 and 
december 1988 were included in this study (n=140). 
Clinicopathological information and transurethral resection specimens were 
collected prospectively. Staging was carried out according to the TNM sys-
temlO and grading into two groups, low and high-grade, according to our 
criteria described elsewhere.ll Complete follow-up data up to december 1989 
or until the time of death were obtained for all patients. The median follow-
up was 21 months (minimum, 1 month; maximum, 109 months). Follow-up 
was conducted at least semi-annually by cystoscopy. 
Of the 125 evaluable cases 60 patients underwent only transurethral resection 
of the tumour and 34 patients received adjuvant intravesical therapy. The 
other 31 patients did receive radiotherapy, cystectomy or a combination of 
both. 
As follow-up criteria we used survival. progression and recurrence. Progres-
sion and recurrence were assessed by pathologists without knowledge of any 
previous clinical data. 
3.3.1 Immunohistochemistry 
Routinely formalin fixed (10% formaldehyde in phosphate buffered-
saline[PBS]) and paraffin embedded tissue blocks of the transurethral resec-
tions were sectioned at 4 11m. Sections were deparaffinized, rehydrated and 
pretreated with pepsin (Sigma Chemical Co., St. Louis, MO) (0.1% in 0, 1 
Normai[N] hydrochloric acid[HCL] for 30 minutes at room temperature) to 
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enhance immunoreactivity. Endogenous peroxidase was blocked in 0.3% 
hydrogen peroxide (H202) in methanol for 30 min. After washing in PBS (3x5 
min) the sections were incubated with polyclonal anti type IV collagen an-
tiserum (diluted 1: 3000 in PBS with 1% bovine serum albumin[BSA]) and 
polyclonal anti laminin antiserum (diluted 1: 100 in PBS with 1% BSA) over-
night at 40 C in a moist chamber. Both primary antisera were raised in rabbits. 
Their immunospecificity was documented previously.l2, 13 
After washing in PBS the sections were incubated with peroxidase- labelled 
swine anti-rabbit Ig antibodies (Dako, Copenhagen, Denmark) (diluted 1: 40 
in PBS with 1% BSA) for 30 minutes at room temperature. After final washing 
with PBS a diaminobenzidin H202 substrate was used to visualize the im-
munoreactivity. In 125 cases satisfactory immunohistochemistry was ac-
complished, which was assessed using blood vessels as internal control. For 
statistical evaluation the immunoreactivity of BM at the tumour I stromal 
interface was scored semiquantitatively into two patterns as follows: (1) 
tumours with intact BM; and (2) tumours with patchy or absent BM. 
3.3.2 Chromosomal analysis 
For microscopic analysis of chromosomes, tumour samples were collected in 
0.5 %sodium citrate with 0.5 ~g/ml colcemid. After incubation for 1. hour at 
room temperature, the tissue was mechanically desegregated in 5 rnl Hanks 
balanced sodium solution (Hanks BSS). Afterwards a solution of 19 m1 Hanks 
BSS and 6 ml colcemid was added. After incubation for 30 min at 37oc, 
hypotonic treatment in a solution of 6 m1 fetal calf serum (FCS) and 24 m1 
0.052 mol/! potassium chloride was followed by fixation in methanol-acetic 
acid 7: 3. Chromosomes were routinely stained with Giemsa. This direct 
method has been described elsewhere in detai!.l4 
Analyzable metaphases, at least five (mean 28) per case were photographed 
and underwent karyotyping according to the Paris nomenclature.l5 The 
tumours were classified according to their modal chromosome number and 
chromosome range. The latter classification distinguishes the tumours with 
diploid or hypodiploid (46 chromosomes or less) cells from those with hyper-
diploid (more than 46 chromosomes) cells. 
3.3.3 Statistical analysis 
Prognostic factors that were included in the analyses, besides BM pattern, 
were as follows: age, sex, T category (stage), histological grade, ploidy and 
therapy. 
Kaplan-Meier survival curves16 for time to death, progression and recurrence 
were analysed by the log-rank test.17 The association between the various 
prognostic parameters was analysed using a chi square-test. When a sig-
nificant difference between the groups with a different pattern of BM deposi-
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tion occurred, a multivariate analysis using Cox proportional hazards 
modeJ18 was executed, to determine the prognostic value of BM continuity 
after correction for the mentioned extraneous prognostic factors. All statisti-
cal analysis were conducted with the BMDP statistical package (BMDP statis-
tical software Inc, Los Angeles, CA). 
3.4 RESULTS 
3.4.1 Immunohistochemical findings 
Paraffin sections of 140 transitional cell carcinomas of the bladder were 
stained. Both antisera against type IV collagen and laminin showed strong 
staining of blood vessels and around muscle fascicles. Only when these 
internal controls stained properly the immunostaining was considered to be 
appropriate. In most cases laminin staining was somewhat weaker than stain-
ing with type IV collagen. In 125 cases reliable immunohistochemical evalua-
tion could be performed. Cases with unreliable immunostaining were found 
to be evenly distributed over low- and high-grade malignant bladder car-
cinoma categories. 
3.4.2 Clinicopathological data 
Of the 125lesions that could be analysed, 52 showed almost intact BM and 73 
lesions showed patchy or absent BM (Figs. 1, 2 and 3). In these tumours the 
tumour stage could not be established with certainty in the HE stained 
sections in eight of 125 cases (6%). Of 46 tumours with intact BM staining 38 
were non infiltrating in the H & E stained sections (82.6%). Of 71 tumours 
with patchy or absent BM staining 58 were infiltrating in H & E-stained 
sections (81.7%). A strong correlation was observed between T-category and 
BM staining (chi-square=48.6, P < 0.0001) (Table 1), as well as between grade 
Table 1. BM expression versus stage of infiltration (T) 
BM 
BM! 
BM!l 
Total 
Stage 
Ta 
38 
13 
51 
Tl 
8 
39 
47 
T2!f3 
0 
19 
19 
Total 
46 
71 
117 
BM !=intact basement membrane; BM ll=interrupted or absent basement membrane; chl-
square=48.6, P < 0.0001. 
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Table 2 .. BM expression versus tumour grade. 
BM 
BMI 
BMII 
Total 
Histological Grade 
Low-grade High-grade 
29 24 
8 64 
37 88 
Total 
53 
72 
125 
BM I=intact basement membrane; BM ll=interrupted or absent basement membrane; chi-
square=28.8, P < 0.0001 
Table 3. BM expression versus chromosomal numbers. 
BM 
BMI 
BMII 
Total 
Chromosomal number 
Diploid Hyperdiploid Total 
20 
4 
24 
19 
57 
76 
39 
61 
100 
BM I=intact basement membrane; BM ll=interrupted or absent basement membrane; chl-
square=27.9, P < 0.0001 
and the BM staining pattern (chi-square=28.8, P < 0.0001). Of 37 low-grade 
lesions 29 showed intact BM (78.4%), whereas of 87 high-grade lesions only 
24 showed intact BM (27.5%) (Table 2). A correlation was also found between 
ploidy and BM staining (chl-square=27.9, P < 0.0001). In 100 out of 125 cases 
chromosomal analysis could be successfully performed. Of the 24 diploid 
tumours 20 showed intact BM (83.3%), of the 76 hyperdiploid tumours 19 
showed intact BM (25.0%) (Table 3). 
The eight cases in which the stage could not be established with certainty 
were all of high-grade malignancy. ln seven of them chromosomal analysis 
was performed. Of these cases six were hyperdiploid and one was diploid. 
With BM staining it was possible to establish the correct stage in all eight 
cases. Microinvasive growth was seen in four tumours while the other four 
were non-invasive. Of the 4 patients with infiltrating tumour, one showed 
progression and eventually died of metastatic disease after 14 months. 
Another of these patients died of unrelated disease after two months. One of 
the patients with a non-infiltrating tumour died after 30 months without any 
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Figure 1. Transitional cell carcinoma with continuous BM 
staining. 
Figure 2. Transitional cell carcinoma with interrupted BM 
staining and micro-invasive growth in the lamina propria. 
Figure 3. Transitional cell carcinoma without normal BM 
staining. 
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Figure 4. Recurrence free-survival. !=intact BM (n=52), II=patchy or absent BM (n=53). (Log 
rank test chi-square=0.350, P = 0.5542). 5 year recurrence free survival: BM 1=44.7% (se 8.8), 
BM 11=36.5% (se 1 1.8) 
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Figure 5. Progression-free survival. !=intact BM (n=52), Il=patchy or absent BM (n=73). (Log 
rank lest chi-square=3.906, P = 0.0481). 5 year progression-free survival: BM 1=81.0% (se 6.5), 
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Figure 6. Survival data of intact versus patchy or absent BM expression. I= Intact BM (n=52), 
Il=patchy or absent BM (n=73). 
(Log-rank test chi-square=8.45, P = 0.0037). 5 year survival: BM 1=61.1 (se8.4), BM ll=32.0 (se 7.3). 
sign of bladder tumour. All other five patients are alive without disease. The 
median follow-up for these 8 cases was 23 months (minimum, 2 months; 
maximum, 49 months). 
The association between BM staining and the subsequent clinical course was 
further assessed. The BM staining pattern proved to be of no value for the 
prediction of recurrence-free survival (Fig 4). There was, however, a border-
line significant correlation between BM staining pattern and progression-free 
survival (log-rank chi-square=3.906, P = 0.048). As is shown on actuarial 
survival curves (Fig.S) patients with tumours with intact BM showed less 
progression than patients with tumours with patchy or absent BM. 
We also found a significant correlation between survival and BM staining 
patterns (log-rank chi-square=8.45, P = 0.004). Patients with tumours with 
intact BM showed a highly significant longer survival than those with 
tumours with interrupted or absent BM (Fig. 6). 
In view of the effects on survival and progression-free survival, we studied 
the interrelation between different variables using Cox proportional hazards 
modeJ.16 We first calculated the univariate prognostic value for survival and 
progression-free survival regarding age, grade, stage, ploidy and therapy. 
Age did not influence the correlation between BM staining pattern and sur-
vival parameters. Stage, however, largely eliminated the value of BM expres-
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sion as a prognostic indicator. Also, the other variables, such as grade, ploidy 
and therapy did not show a significant independent correlation with survival 
and progression-free survival in addition to tumour stage. 
In the group of high-grade tumours (n=87) 26% showed intact and 74% 
showed patchy or absent BM staining. A slight difference in survival was 
observed, which appeared not to be statistically significant (chi-squar•e=2.234, 
P = 0.135). The same was observed for progression-free survival (chi-
square=l.533, P = 0.216). 
When we evaluated the hyperdiploid group (tumours with more than 46 
chromosomes per cell), 19 out of 76 tumours (25.0%) showed intact BM, while 
57 tumours showed patchy or absent BM (75.0%). Between these groups we 
found no differences in survival or progression-free survival. A slight, but not 
significant difference in survival was seen between the two BM patterns in 
stage Ta (chi-square=l.754, P = 0.1854). In stage T1 tumours BM pattern did 
not correlate with survival. Likewise, the BM pattern did not correlate with 
progression-free survival in Ta or in Tl tumours. 
3.5 DISCUSSION 
In carcinomas, a dynamic interaction occurs at the interface between tumour 
cells and the surrounding mesenchymal stroma. Collagenases, including type 
IV-specific collagenase and other proteases, such as plasminogen activators, 
cathepsins and heparanases form a cascade system of enzymes facilitating 
extra cellular matrix breakdown), 19,20 Conversely, as a host reaction to the 
invading neoplasm, extracellular matrix components, including BM material 
and interstitial collagen, may also be deposited around tumour cells.21, 22 A 
desmoplastic stromal reaction around tumour cells, involving myofibro-
blasts, might play a role in BM deposition at the tumour stromal interface. 
Numerous immunohistochemical studies have documented loss of continuity 
of BM in many different malignant neoplasms.l, 5-9,23-25 
The initial working hypothesis of these studies was that in benign (nonin-
vasive) neoplasms an intact BM would be found, whereas in invasive malig-
nant neoplasms, the BM would be interrupted or absent. This has proven to 
be an oversimplification, as also reflected in the results we obtained. On one 
hand some noninvasive bladder tumours showed discontinuities in the BM, 
whereas on the other hand some invasive bladder carcinomas showed intact 
BM. We then argued that a positive balance between deposition and break-
down of BM components, resulting in intact BM, could be a sign of competent 
host response to the neoplasm. This might correlate with a better prognosis. 
In the present study a direct correlation between T category and BM loss was 
observed. A proportion of the Ta lesions (intraepithelial tumours) showed 
incomplete BM, suggesting that although invasion had not yet occurred, there 
was already significant discontinuity of the BM barrier. Conversely some of 
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the Tllesions (tumours with invasion into the lamina propria) showed intact 
BM, reflecting the production of BM components even in invasive carcino-
mas. Conn et a!. reported similar observations in their study on bladder 
carcinoma.S Daher et a!. reported intact as well as interrupted BM in T1 
tumours9 In their study no information was presented concerning Ta 
tumours. 
Long-term follow-up studies are necessary to evaluate the biological sig-
nificance of these observations. Statistical evaluation of clinical follow-up 
data in our study resulted in a highly significant correlation between BM 
deposition pattern and survival. Furthermore a borderline significant correla-
tion between progression-free survival and BM deposition pattern was 
found. According to both survival parameters patients with tumours with 
intact BM had a better prognosis than patients with tumours with patchy or 
absent BM. No correlation was found with the recurrence- free survival, the 
mean number of recurrences per year and the recurrence rate. 
These results are in concordance with the literature in regard of recurrence-
free survival and progression-free survivaLS As to survival, the only com-
parable data are found in the study of Daher at aJ..9 They documented a 
significant difference in short-term survival between their two groups of BM 
staining pattern, which did not include Ta tumours. 
Our material was also analysed for a number of additional parameters. For 
each parameter the prognostic value was calculated. All parameters with a 
significant correlation with survival or progression-free survival were further 
tested by a multivariate analysis. ln the Cox proportional hazard model the 
additional value of BM deposition pattern was calculated after correction for 
other parameters. The following variables were found to have prognostic 
value: age, stage of the tumour, histological grade and ploidy. We found that 
tumour stage was the most important independent prognostic parameter for 
survival (Log-rank test chi-square=21.6, P < 0.0001) and progression-free 
survival (Log-rank test chi-square=9.88, P = 0.0017). The other variables did 
not add essential additional information. 
In contrast with earlier studies, 8, 9 our results document that as a prognostic 
indicator BM staining is of limited additional value in comparison with grade 
and stage. Nevertheless, BM staining is of practical value for correct staging 
of bladder carcinomas because in 8 of 125 cases (6%), the tumour stage could 
not be established with certainty in the H & E stained sections. Basement 
membrane staining, which can be performed on routinely fixed and em-
bedded material, facilitates the assessment of microinvasive growth of blad-
der cancer, which may be overlooked or only suspected in the H & E stained 
sections. As such this rather simple technique is indirectly important for 
prediction of survival and progression-free survival, because it helps to esta-
blish the correct stage of the neoplasm. 
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4.1 ABSTRACT 
Of 294 patients with primary transitional cell carcinoma (TCC) of the urinary 
bladder, tumour samples were studied by selective nuclear morphometry as 
a quantitative measure of nuclear grade. We found a strong association with 
the "classic" parameters stage, grade and mitotic index. In WHO grade II 
tumours morphometric heterogeneity could be demonstrated. There was a 
significant difference in survival between morphometrically determined low-
grade malignant cases and high-grade malignant cases, the presence of large 
nuclei (>95J.lm2) indicating poor prognosis. The morphometrically deter-
mined grade was also found to be a strong predictor of tumour progression. 
In multivariate analysis, combining histopathological and morphometric fac-
tors, only pathological stage and mitotic index proved to be independent 
predictive factors. 
It is concluded that grading by means of morphometry, as a single factor, is 
correlated with survival and tumour progression and therefore this 
parameter is useful in addition to the classical parameters stage and grade, 
especially in WHO grade II TCC. 
4.2 INTRODUCTION 
The urinary bladder is the site of origin of a variety of benign and malignant 
neoplasms. The most important group of tumours consists of epithelial 
tumours of transitional cell type. One of the most keenly awaited advances in 
the management of bladder cancer is a means of assessing the biological 
potential of a tumour at, or soon after, the patients initial presentation. At 
present the decision on treatment of bladder tumours is based on the TNM 
classification, 1 with an emphasis on staging and on histological grading 
using the WHO system.2 However in the WHO grading system a sharp 
demarcation between different grades cannot be attained. This results in 
considerable interobserver variability and therefore poor agreement between 
diagnoses made by different pathologists}, 4 Unfortunately, also staging has 
its problems. The pathologist's interpretation of infiltration in theTa and T1 
group of tumours is sometimes inconsistent and not always reproducible, 5 
notably when the biopsy does not contain all layers of the bladder wall. 
Therefore, other potential predictors of disease evolution have been searched for. 
Flow cytometry, 6-9 image cytometry, 10 mitotic activityll and nuclear mor-
phometry4. 12, 13 have been used to grade bladder cancer, with promising results. 
The purpose of the present study was to determine the extent to which the 
biological potential of TCC. in terms of survival and progression-free sur-
vival, can be predicted by morphometrical grading of the primary tumour in 
a two grade system, especially when compared and combined with other 
prognostic factors like stage, grade, mitotic index and age. 
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4.3 MATERIALS AND METHODS 
This study was based on clinical follow-up of 294 consecutive patients with 
TCC of the bladder. These were all primary tumours diagnosed between 1979 
and 1991. Of these patients 53 (18%) were female (mean age 70 years) and 241 
(82%) were male (mean age 66 years). These patients were treated and fol-
lowed up during 1979-1992. The median follow-up was 46 months, with a 
maximum of 163 months (mean follow-up 54 months). Follow-up examina-
tions were conducted at least semi-annually and included cystoscopy and 
urinary cytology. As follow-up criteria survival and progression-free interval 
were chosen. Progression was defined as increase in stage or death due to 
tumour. If a patient was lost to follow-up, survival was assessed by contact-
ing municipal population registries or family doctors. 
Staging was carried out according to the UICC criteria I and grading accord-
ing to the WHO criteria.2 
We furthermore estimated the mitotic index, using the counting method as 
described elsewhere.l4 We counted 10 fields using a xlO ocular and a x40 
objective with a numerical aperture of 0.75 and a field width of 450 J.Ull 
(counts/10 hpf). The criteria described by Baak were used to identify mitotic 
figures.l5 
4.3.1 Morphometry 
For morphometric measurements we used the "VIDEOPLAN" image 
analyzer (Kontron, Munich, Germany). The most atypical fields were selected 
in approximately Slow power fields and subsequently 10 nuclei were selected 
on account of their large size. This method has shown satisfactory intra- and 
interobserver reproducibility.4 The patient group was subdivided into two 
groups on account of the mean nuclear area. The low-grade malignant group 
had small nuclei (mean nuclear area ~95j.lm2) and the high-grade malignant 
group had large nuclei (>95j.lm2). 
4.3.2 Statistical analysis 
Prognostic factors that were included in the analysis were: Morphometric 
grading (low-grade; high-grade), WHO grading (grade I; II; III), T category 
(stage Ta; T1; T2 or more), mitotic index (5 or less mitoses/10 hpf; more than 
5 mitoses/10 hpf), age (70 or less years; more than 70 years) and sex. For each 
prognostic factor Kaplan Meier survival curves16 were analysed by means of 
the log-rank test17 with regard to time interval to death and time interval to 
establishment of progression. A possible association between various prog-
nostic factors was analysed using the Pearson chi- square test. 
Furthermore, multivariate survival analyses were performed using Cox 
proportional hazards model .IS In these models, low /high grading was in-
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eluded together with the mentioned other factors. The stepwise method was 
used to select the model, with use of the likelihood ratio test. A P-value of 0.05 
was adopted as limit for entering and removing covariates. Of the prognostic 
factors, that contributed significantly to the model, the effect was calculated 
in terms of relative risk and the associated 95% confidence interval. The 
statistical analyses were performed with the SAS statistical package (SAS lnst 
Inc, Cary, North Carolina, USA). 
4.4 RESULTS 
According to the morphometric values 108 TCC were classified as low-grade 
malignant and 186 TCC as high-grade. 
Strong association was observed between morphometric grades, WHO 
grades, stage and mitotic index (P < 0.0001) (Table 1). 
4.4.1 survival 
The WHO grade II tumours could be divided by morphometry into two 
groups with significantly different survival (P = 0.02) (fig. 1). 
For morphometric grading we found a significant difference in survival (P < 
0.0001) (fig. 2). Of the 108 patients with morphometric low-grade tumours, 5 
died of tumour related disease and 31 died of unrelated causes of d'eath. Of 
the 186 patients with high-grade tumours 44 died of tumour related disease 
and 65 died of unrelated causes of death. Other strong predictors of survival 
were stage (P < 0.0001) (fig. 3), age (P < 0.0001) and mitotic index (P < 0.0001). 
In multivariate analysis, stage (P < 0.0001) was the most important factor. The 
other factors (except age) did not contribute significantly to the prediction. 
4.4.2 progression 
The WHO grade II tumours could be separated by morphometry into two 
groups with a significantly different tendency for progression (P = 0.0115) 
(fig. 4). 
We found a significant association between morphometric grades and 
progression (P < 0.0001) (fig. 5). Other strong predictors of progression were 
stage (P < 0.0001) (fig. 6), mitotic index (P < 0.0001) and WHO grades (P < 
0.0001). 
ln the multivariate analysis stage was again the most important prognostic 
parameter in predicting progression (P < 0.0001) next to the mitotic index (P 
= 0.0022). The other variables did not show significant independent predic-
tive value. 
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Table 1. Association between morphometric grading, WHO-grading, stage and mitotic index. 
morphometric grading 
LOW HIGH Total 
WHO grading I 54 14 68 
II 54 132 186 
lll 39 40 
Stage Ta 89 59 148 
Tl 18 77 95 
T2+ 2 49 51 
Mitotic index OS:5 87 69 !56 
>5 22 116 138 
Total 109 185 294 
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Figure 1. Overall survival according to WHO grades. WHO grade II rumours are devided into 
two diffeJrent prognostic subgroups (ITa and llb) on account of the mean nuclear area; I=WHO 
(n~68); II~ WHO II (n~186); III~ WHO III (n~40); 5 year survival: 1~79.9% (95% C!, 69.7-90.2), 
IIa~71.3% (95% Cl, 58.3-84.3)(n~53), Ilb~50.9% (95% CI, 42.1-59.6)(n~l33),III~l9.7% (95% C!, 
7.2-32.1). 
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Figure 2. Overall survival according to morphometric grades. !=low-grade (n=108), II=high-
grade (n=186). 5 year survival: !=77.1% (95% 0, 68.7-85.4), 1!=45.2% (95% Cl, 37.8-52.7). 
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Figure 3. Overall survival according to tumour stage (T). l=Ta (n=147), II=Tl (n=94), ill=T2 or 
more (n=50); 5 year survival: !=76.4% (95% Cl, 69.1-83.6), 1!=47.6% (95% Cl, 37.1-58.2), 
ID=16.4% (95% 0, 5.5-27.2). 
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Figure 4. Progression-free survival according to WHO grades. WHO grade IT tumours 
separated into different subgroups (Ila and lib) on account of mean nuclear area. l=WHO I 
(n=68); II=WHO II (n=186); IIl=WHO II1 (40); 5 year progression-free survival: 1=93.2% (95% 
CI, 86.5-99.8), 1Ia=87.9% (95% Cl, 78.9-97.0)(n=53), 1Ib=69.3 (95% CI, 60.8-77.8)(n=133), 
II1=33.3% (95% CI, 17.3-49.4). 
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Figure 5. Progression-free survival according to morphometric grades. !=Low-grade (n=108), 
II= High-grade (n=186); 5 year progression-free survival: !=90.6% (95% CI, 84.6-96.6), II=63.5% 
(95% Cl, 56.0-70.9). 
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Figure 6. Progression-free survival according to tumour stage (T).l=Ta (n=147), II=Tl (n=94), 
ill=T2 or more (n=50); 5 year progression-free survival: 1=91.9% (95% 0, 87.0-96.8), II=65.6% 
(95% CI, 55.3-75.8), ill=32.5% (95% CI, 18.2-46.8). 
4.5 DISCUSSION 
Bladder cancer has an unpredictable clinical course. Treatment is still general-
ly based on histopathological grade and stage. The most widely accepted 
histopathological grading system is the three grade system proposed by the 
WH0.2 However, the criteria for the different grades are considered to be 
rather vague, resulting in considerable intra- and interobserver variability.3· 4 
Staging, especially in superficially infiltrating tumours, also is not sufficiently 
reproducible. The resolution of these problems can be assisted by using 
immuno-staining techniques to stain the basement membrane, which helps in 
assessing infiltrative growth.19 Nevertheless, when the biopsy is inadequate 
and does not contain all layers of the bladder wall, staging cannot be per-
formed with certainty. 
For adequate clinical management of TCC it would be useful to have a 
parameter (s) that would allow early recognition of those patients who have 
a high risk for tumour progression and consequently for dying of the tumour. 
For the pathologist, such a test ideally should be simple and reproducible. 
Morphometry appears to satisfy most of these criteria as has been pointed out 
by different authors in showing the usefulness of nuclear morphometry for 
the objective assessment of tumour grade in bladder carcinoma.3• 4, 20 Mor-
phometric grading was found to be of prognostic significance in the predic-
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tion of survival and of tumour progression.4, 13, 21-23 However, in these 
studies these parameters were not tested for their prognostic value when 
compared with the conventional prognostic factors. Blomjous et al. described 
a method of morphometry in which, after selection of the most atypical areas 
of the tumour, only the ten largest nuclei were measured.4 Two mor-
phomebric grades were proposed based on mean nuclear area. 
In the present study, these morphometric grades showed a highly significant 
association with the histopathological parameters (stage, grade and mitotic 
index). As to the prediction of clinical outcome, morphometric grading 
showed a significant correlation with survival and tumour progression. The 
additional value of this parameter was tested by multivariate analysis, also 
taking into account other parameters, that are significantly correlated with 
survival. and tumour progression i.e. stage, grade and mitotic index. 
The results indicate that stage is the only independent histopathological 
paramelter significantly correlated with survival. Morphometric grading has 
no additional independent value in this respect. Also in predicting tumour 
progression, stage is the most significant parameter, the mitotic index being 
the only other independent predictor. 
In conclusion, morphometry appears to be an objective method in grading 
TCC. A high morphometric grade is correlated with aggressive tumour be-
haviour. However, as shown by multivariate analyses, tumour stage remains 
the most important predictor of survival and tumour progression. When 
histopathological staging cannot be performed reliably morphometry can be 
of use in separating tumour groups with different clinical behaviour especial-
ly in WHO grade ll tumours. When a TCC has a high morphomebrical grade 
infiltration is very likely. 
59 
MORPHOMETRY AND BLADDER CANCER 
4.6 REFERENCES 
1. HERMANEK, B., SOBIN, L. H. (1987). In T.N.M. Classification of Malignant Tumours, Union 
International Contre le Cancer (UlCC), ed. 4, pp. 121-144. New York: Springer-Verlag. 
2. MOSTOFI,F.K. (1973).1n: Histological typing of Urinary Bladder Tumours,Internatio111ll Histologi-
cal classification of Tumours. No. 10, World Health Organization (WHO), Geneva. 
3. OOMS, E.C.M., ANDERSON, W.A.D., ALONS, C.L., BOON, M.E., VELDHU!ZEN,R.W. (1983). Analysis 
of the performance of pathologists in the grading of bladder tumours. Hum. Pathol., 14, 
140-143. 
4. BLOMJOUS, C.E.M., SMEULDERS, A.W.M., BAAK, J.P .A., VOS, W., VAN GALEN, E.M., MEJ)ER, Cj.L.M. 
(1989). A comparative study in morphometric grading of transitional cell carcinoma of the 
urinary bladder. Anal. quant. cytol. histol., 11, 426-432. 
5. REUTER, V.E. (1990). Pathology of Bladder Cancer: Assessment of Prognostic Variables and 
Response to therapy. Seminars in Oncology? 17, no 5, 524-532. 
6. OLJANS,P.J., TANKE, H.J. (1986). Flow cytometric analysis of DNA content in bladder cancer: 
prognostic value of the DNA- index with respect to early tumour recurrence in G2 
tumours. World f. Ural., 4, 205-210. 
7. BLOMJOUS, C.E.M., SCHIPPER, N.W., BAAK,J.P.A., VAN GALEN, E.M., DE VOOGT, H.)., MEIJER, C.j.L.M. 
(1988).Retrospective study of prognostic importance of DNA flow cytornetry of urinary 
bladder transitional cell carcinoma. f. Clin. Pathol., 41,21-25. 
8. DEVERE WHITE, R.W., DEITCH, A.D., WEST, B., FITZPATRICK, j.M. (1988). The predictive value of 
flow cytometric information in the clinical managerneot of stage 0 (Ta bladder cancer. f. 
Ural., 139, 279-285. 
9. SHAABAN, A.A., TRIBUKAIT, B., EL·BEDEIWY, A.A., GHONEIM, M.A. (1990). Prediction of lymph 
node metastases in bladder carcinoma with deoxyribonucleic acid flow cytometry. J. Ural., 
144, 884-887. 
10. STOCKLE, M., TANKE, H.)., MESKER, W.E., PLOEM, ).S., JONAS, U., HOHENFELLNER, R. (1987). 
Automated DNA-image cytometry: a prognostic tool in infiltrating bladder carcinoma. 
World f. Ural., 5, 127-132. 
11. VASCO,)., MALMSTROM, p.u., TAUBE, A., WESTER, K., BUSCH, C. (1991). Prognotic value of a 
systematized method for determination of mitotic frequency in bladder cancer assisted by 
computerized image analysis. f. Urogenital Pathol., 1,53-59. 
12. NIELSON, K., ORNTOFT, T., WOLF, H. (1989). Stereological estimates of nuclear volume in 
non-invasive bladder tumours (Ta correlated with the recurrence pattern. Cancer, 64, 
2269-2274. 
13. LIPPONEN, P.K., COLLAN, Y., ESKELINEN, M.j., PESONEN, E., SOTARAUT A, M., NORDLING, S. (1990). 
Comparison of morphometry and DNA flow cytometry with Standard Prognostic Factors 
in Bladder Cancer. Brit. f. Ural., 65, 589-597. 
14. VAN DIEST, P.j., BAAK, )I' A., MATZE.C:OK, P., WISSE- BREKELMANS, E.CM., VAN GALEN, C.M., 
KURVER, P.H.J., BELLOT, S.M., Fl)NHEER, )., VAN GORP, L.H.M., KWEE, W.S., LOS, )., PETERSE, J.L., 
RUITENBERG, H.M., SCHAPERS, R.F.M., SCHIPPER, ME.!., SOMSEN, ).G., WILLIG, A.W.P.M., ARIENS, 
A.TH. (1992). Reproducibility of mitosis counting in2, 469 breast cancer specimens: Results 
from the multicenter morphometric manunary carcinoma project. Hum. Pathol., 23, 603-
607. 
15. BAAK, J.P.A., OORT, J. (1983). Obtaining Quantitative Data. In: A manual of morphometry in 
diagnostic pathology, pp. 18-20. Berlin: Springer-Verlag. 
16. KAPLAN, E.L., MEIER, P. (1958). Non parametric estimation from incomplete obsenration. f. 
Am. Stat. Assoc., 53, 457- 481. 
60 
MORPHOMETRY AND BLADDER CANCER 
17. PETO .. R., PIKE, M.C., ARMITAGE, P., BRESLOW, N.E., COX, D.R., HOWARD, S.V., MANTEL, N., 
MCPHERSON, K., PETO, )., SMITH, P.G. (1977). Design and analysis of randomised clinical trials 
requiring prolonged observation of each patient: II. Analysis and examples. Br. J. Cancer, 
35, 1-39. 
18. COX, D.R. (1972). Regression models and live tables.]. Roy. Stat. Soc., 34: 187-220. 
19. SCHAPERS, R.F.M., PAUWELS, R.P.E., HA VENITH, M.G., SMEETS, A.W.G.B., VAN DEN BRANDT, P.A., 
BOSMAN, F.T. (1990). Prognostic significance of type N collagen and laminin immunoreac-
tivity in urothelial carcinomas of the bladder. Cancer, 66, 2583- 2588. 
20. OOMS, E.C.M., BLOK, A.P.R., VELDHUIZEN, R.W. (1985). The reproducibility of a quantitative 
grading system of bladder tumours. Histopathology, 9, 501-509. 
21. DESANCTIS, P.N., CONCEPCION, N.B., TANNENBAUM, M., OLSSON, C. (1987). Qualitative mor-
phometry measurements of transitional cell bladder cancer nuclei as indicator of tumour 
aggression. Urology, 29, 322-324. 
22. MONTIRONI, R., SCARPELLI, M., ANSUINI, E. MARINELLI, F., MARIUZZI, G. (1986). Quantitative 
evaluation of the progressive nuclear abnormalities in urothelial papillary lesions. Appl. 
Pathol., 4, 65-73. 
23. QING-BEI YANG, YANG-ZHI XIA, ZHI-YOUNG WANG, GUANG-)UN WANG, SHU-ZHE DING, DIAN-
ZHI SHI, WEN-DE LIU (1991). Morphometric diagnosis of bladder tumour. Oncology, 48, 
188-193. 
61 

DNA ANALYSIS AND BLADDER CANCER 
CHAPTERS 
IMAGE CYTOMETRIC DNA 
ANALYSIS IN TRANSITIONAL CELL 
CARCINOMA OF THE BLADDER 
RENE F. M. SCRAPERS 
JOKE J. PLOEM-ZAAIJER 
RUUD P. E. PAUWELS 
A. WIM G. B. SMEETS 
PIET A. van den BRANDT 
HANS J. TANKE 
FRE T. BOSMAN 
From the Departments of Pathology[RFMS] and Urology[RPEP], the Stichting 
Ziekenhuizen Venlo-Venray, Venlo: the Department of Cytochemistry and Cytometry, 
University of LeidenUJP-Z, H)T]: the Department of Clinical Pharmacy and 
Laboratory[AWGBS], Venray, the Department of Epidemiology[PAvdll], University of 
Limburg, Maastricht: the Department of Pathology[FTB], Erasmus University, Rotterdam, 
The Netherlands. 
Cancer, 72,182-189,1993 
63 
DNA ANALYSIS AND BLADDER CANCER 
5.1 ABSTRACT 
Background. The current study was initiated to investigate measurable objec-
tive and reproducible characteristics that might have prognostic significance 
in bladder cancer. 
Methods. Tumour samples from 91 patients with primary transitional cell 
carcinoma (TCC) of the urinary bladder, were studied by DNA image 
cytometry and cytogenetic analysis. Image cytometry is a more sensitive 
method of determining ploidy than flow cytometry, especially in tumours 
with a low number of aneuploid cells. 
Results. There was a significant difference in survival between DNA image 
cytometry-determined diploid and nondiploid cases. The presence of nuclei 
with a high DNA content indicated poor prognosis. The 2C deviation index 
(2CDI) also was an indicator of survival. Image cytometry-determined factors 
also were found to be strong predictors of progression-free survival. In mul-
tivariate analysis, 2CD! was the only cytometric parameter with an inde-
pendent but weak correlation with survival. In multivariate analysis, none of 
the cytometric parameters had an important contribution to prediction of 
progression-free survival. 
In superficial tumours (Ta and Tl), 2CD! appeared to be the most important 
independent predictor of survival. With respect to progression-free survival, 
tumours with a high mitotic index proved to have a worse prognosis. 
Conclusions. Parameters determined by DNA image cytometry appear to be 
valuable in predicting survival and progression-free survival and may be 
useful in addition to the classic parameters of stage and grade, especially in 
superficial TCC. 
5.2 INTRODUCTION 
Urothelial cancer displays unpredictable variations in biological behaviour. 
Histopathological characteristics of transitional cell carcinoma (TCC) have a 
limited predictive value with respect to survival and progression. Therefore, 
other potential predictors of disease evolution have been searched for. The 
current study was initiated in 1979 to investigate measurable objective and 
reproducible characteristics that might have prognostic significance in blad-
der cancer. 
During the last decades, many studies have focused on the DNA content of 
bladder cancer, using image cytometryl-6 as well as flow cytometry (FCM). 
7-10 It has been shown by several authors that valuable prognostic informa-
tion can be obtained from the nuclear DNA distribution pattern using these 
techniques. Aneuploidy, as determined by FCM, appeared to be a parameter 
that could predict which tumours will progress; '9 however, tumours with 
only a few cells with high DNA content against a background of abundant 
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diploid tumour cells might be classified as diploid by FCM and this approach 
therefore lacks sensitivity. 
The purpose of the current study therefore was to determine the potential use 
of image cytometry in providing parameters that might be useful in predict-
ing the biological behaviour of the neoplasm. Special attention was given to 
the potential value of rare incidents (e.g., occasional cells with a very high 
DNA content). The cytometric parameters were compared to those from 
conventional cytogenetic analysis and other prognostic factors. 
5.3 MATERIALS and METHODS 
Between January, 1979 and May, 1991 bladder carcinoma was diagnosed for 
the first time in 399 patients. Over this period, 156 specimens were subjected 
to cytogenetic analysis. Representative paraffin blocks of 143 of these 156 
specimens were available for image cytometric DNA analysis. To reduce the 
influence of therapy on survival, only patients undergoing transurethral 
resection of the tumour, without any other radical therapy (radiation therapy, 
cystectomy, or both), were included in this study (n=91). Clinicopathological 
information and transurethral resection specimens were collected prospec-
tively. Staging was carried out according to the TNM system, 11 and grading 
into two groups, low and high-grade, was done according to criteria 
described elsewhere12 (low-grade tumours are grade 1 and 2a; high-grade 
tumours are grade 2b and 3). We also estimated the mitotic index, which 
expresses the number of mitotic figures per 10 high-power fields (hpf, x40) of 
neoplastic tissue.13 The criteria of counting mitoses described by Baak and 
Oort were used.l4 
The median follow-up was 30 months, with a maximum of 112 months (mean 
follow-up, 36.7 months). Follow-up examinations were conducted at least 
semiannually in all patients and included cystoscopy and urinary cytological 
analysis. Survival and progression-free survival were chosen as follow-up 
criteria. Progression, defined as increase in stage at recurrence or death, was 
assessed histologically by pathologists without knowledge of previous diag-
nostic information and clinical data. If a patient was lost to follow-up, sur-
vival was assessed by contacting municipal population registries. 
5.3.1 DNA Image Cytometry 
Automated image analysis was performed with Leytas (Leica, Wetzlar, Ger-
many) on slides made from nuclear suspensions obtained from 50-~m sec-
tions, cut after each section from a paraffin-embedded tumour block used for 
histological analysis. The procedure for the preparation of nuclear smears 
from paraffin-embedded tissue has been described in detail elsewhere.l5 
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Briefly, the sections were dewaxed with xylene, rehydrated in decreasing 
concentrations of ethanol, digested in a solution of 0.05% pronase in phos-
phate- buffered saline at 37oc for 30 minutes and resuspended mechanically. 
The cell suspension was diluted to a value of about 20, 000 epithelial cells/ml 
and monolayer preparations were obtained by cytocentrifugation. DNA 
staining was performed with acriflavine-Feulgen. Automated image analysis 
was carried out with Leytas, as described in detail previously.l6-18 Briefly, 
Leytas consists of an automated microscope (Autoplan, Leica) interfaced to 
an image analysis computer (MIAC). The Autoplan includes one objective 
and two cameras, one for low and one for high magnification. The low-mag-
nification channel was used for automated cell selection on the basis of grey 
level (intensity thresholding) and size. The selection procedure included 
extensive artifact rejection to remove overlapping cells or artifacts. The set-
tings for the cell selection criteria were adapted such that first 250 epithelial 
cells were selected randomly and then the preparation was screened for 70 
cells with higher density and size. 
A high-magnification image was obtained of each selected cell for measure-
ment of cellular parameters. To obtain histograms consisting of single cells 
only, a visual step was included at the end of the measurement procedure to 
remove artifacts not rejected by the automated procedure. This visual evalua-
tion was done by inspection of stored grey value images of the selected 
objects on a television monitor (Fig. 1). 
DNA histograms were obtained by converting measured densities into C 
values with the aid of reference cells (normal epithelial cells or leukocytes). 
When two populations were present in the integrated optical density (JOD) 
histogram, it was assumed that the first population consisted of normal cells. 
The mean IOD of these populations also was used to estimate the 2C value. 
To obtain a reproducible DNA histogram classification, the DNA histograms 
were classified into four categories on the basis of 2C and 5C exceeding rates. 
The first group consists of purely diploid cases with less than 5% of the cells 
outside the 2C population. The second category is referred to as probably 
diploid and includes cases that have up to 10% of cells outside the 2C 
population. As in the diploid category, few cells over 5C are present. The 
third category contains cases with a maximum of 15% cells outside the 2C 
population. In addition, the cells outside the 2C population present a higher 
proportion of cells above 5C (i.e., more than 0.05%). The fourth category 
includes all histograms in which more than 15% of the cells have a DNA 
content higher than the 2C cell population. Typical examples are g~ven in 
Figure 2. 
In addition the number of cells exceeding SC in the total smear (400 micro-
scopic fields) was calculated from the histogram. A third parameter was the 
2C deviation index (2CDI), which calculates the sum of all deviation squares 
of the differences of the DNA values from the 2C value divided by the 
number of measured cells.l9 The 2CDl value thus represents a numerical 
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Figure 1. Stored grey value images of the selected objects on a TV monitor. 
expression of the deviation of the DNA content of the tumour cell population 
from the mean DNA content of a nonproliferating diploid cell population. 
5.3.2 Chromosomal analysis 
A direct method was used for microscopic analysis of chromosomes, as 
described elsewhere in detaiJ.20 Tumour samples were collected in 0.5 % 
sodium citrate with 0.5 ~g/ml colcemid. After incubation for 1 hour at room 
temperature in 5 ml Hanks balanced sodium solution (Hanks BSS), the tissue 
was mechanically desegregated. Next, a solution of 19 ml Hanks BSS and 6 ml 
colcemid was added. After incubation for 30 minutes at 37°C, hypotonic 
treatment in a solution of 6 ml fetal calf serum (FCS) and 24 ml 0.052 mol/1 
potassium chloride was followed by fixation in methanol-acetic acid 7: 3. 
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Chromosomes were routinely stained with Giemsa. lf possible, C- and G-
banding was performed. According to the modal chromosome number (CM), 
the tumours were classified into diploid (46 chromosomes or less) and hyper-
diploid (more than 46 chromosomes). 
5.3.3 Statistical analysis 
Prognostic factors that were included in the analysis were: image cytometric 
ploidy class (four categories), the number of cells exceeding 5C (s; 10 cells or 
> 10 cells per 400 microscopic fields), 2CDI (0.2 or less, between 0.2 and 2.0, 
2.0 or more), CM (diploid, hyperdiploid), low-high grading, T category (Stage 
Ta; Tl; T2+), mitotic index (s;S mitoses/10 hpf; > 5 mitoses/10 hpf), age 
(younger than 70 years; 70 years or older) and sex. For each prognostic factor, 
Kaplan-Meier survival curves21 were analysed by means of the log-rank 
test22 with regard to time interval to death and time interval to progression. 
A possible correlation between various prognostic factors was analysed using 
the Pearson chi-square test. 
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In addition, multivariate survival analyses were performed using the Cox 
proportional hazards modeJ.23 Age was entered as a continuous variable in 
these models. Covariates were deleted in a stepwise manner (backward 
elimination), with use of the likelihood ratio test. A P-value of 0.10 was 
adopted as limit for deletion of a covariate. For the prognostic factors that 
contributed significantly to the model, the effect was calculated in terms of 
relative risk and the associated 95% confidence interval. The survival 
analyses were performed with the BMDP statistical package (BMDP Statisti-
cal Software Inc, Los Angeles, CA). 
5.4 RESULTS 
Of the 91 patients meeting our selection criteria, 71 (78%) were men and 20 
(22%) were women. Age ranged from 26 to 99 years, with a mean of 74 years. 
5.4.1 Correlation between prognostic factors 
Strong correlations were found between stage, histological grade, the 
cytogenetic parameter CM and the cytometrically determined parameters: 
DNA cytometric ploidy class (Table 1), number of cells above 5C (Table 2) and 
2CDI (Table 3; all P < 0.0001). 
Table 1. Tumour stage, grade, modal number of chromosomes(CM) in relation to image 
cytometric ploidy class. 
Stage: Ta 
Tl 
T2+ 
Grade: Low 
High 
CM: Diploid 
Hyperdiploid 
Total 
Image DNA Ploidy 
I 
9 
I 
0 
6 
4 
9 
I 
10 
2 
13 
12 
3 
14 
15 
3 4 Total 
II 10 43 
3 32 37 
0 10 II 
6 6 30 
8 46 61 
12 16 51 
2 36 40 
14 52 91 
image DNA ploidy class 1 = diploid; 2 = probably diploid; 3 = probably aneuploid; 4 = 
aneuploid 
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Table 2. Tumour stage, grade, modal number of chromosomes(CM) in relation to number of 
cells >Sc. 
Number of Cells > 5c 
,;; 10 >10 Total 
Stage: Ta 33 10 43 
T1 6 31 37 
T2+ 10 11 
Grade: Low 25 5 30 
High 15 46 61 
CM: Diploid 36 15 51 
Hyperdiploid 4 36 40 
Total 40 51 91 
Table 3. Tumour stage, grade, modal number of chromosomes(CM) in relation to the 2c 
deviation index. 
2c deviation index 
:>0.2 0.2><2.0 ~2.0 Total 
Stage: Ta 28 12 4 44 
Tl 3 14 19 36 
T2+ 5 5 11 
Grade: Low 18 11 1 30 
High 14 20 27 61 
CM: Diploid 28 21 2 51 
Hyperdiploid 4 10 26 40 
Total 32 31 28 91 
5.4.2 Survival 
In univariate analyses, the parameters correlating with survival were stage 
(log-rank chi-square=15.9; P = 0.0003), mitotic index (log-rank chi-square=5.3; 
P = 0.0208), age (log-rank chi-square = 6.8; P = 0.0093), CM (log-rank chi-
square=12.4; P = 0.0004), DNA cytometric ploidy class (log-rank chi-
square=11.7; P = 0.0085; Fig. 3a), number of cells above 5C (log-rank 
70 
7. 
s 
u 
r 
v 
i 
v 
a 
l 
1,0 
0,9 
0,8 
0,7 
0,6 
0,5 
0,4 
0,3 
0,2 
0,1 
DNA ANALYSIS AND BLADDER CANCER 
: 1!..,-----. 
I H (n=15) 
"!, l 
., -., 
: I 
!_ I 
·• I 
•t:;---- ------------1 I (n=10) 
~-.._ __ _, I 
..... r._ ___ l 
~-:, __ ~ 1 
•- I 
"' 1-----.. 
.. 
·-·-·-· 
III !•=I<l 
'· L-•-·• L---·-
IV (n=52) 
0,0 +---+--+---+--+---t----1 
0 10 20 30 40 
months 
50 60 
Figure 3a. Survival according to the cytometric ploidy class: !=diploid, ll=probably diploid, 
III=probably aneuploid, IV= aneuploid. 
1,0 
0,9 
0,8 
7. 0,7 
s 0,6 
u 
r 0,5 
v 
i 0,4 
v 
a 
0,3 
l 0,2 
0,1 
0,0 
0 10 20 30 40 
months 
I (n=40) 
50 60 
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chi-square=16.1; P < 0.0001; Fig. 3b) and 2CDI (log-rank chi- square=16.4; P = 
0.0003; Fig. 3c). 
ln multivariate analyses, age (likelihood ratio chi-square=14.3; P = 0.0002) 
and stage (likelihood ratio chi-square=12.2; P = 0.0022) were the only 
parameters correlating significantly with survival. The 2CDI was of border-
line significance in this respect (likelihood ratio chi-square= 5.3; P = 0.0698; 
Table 4). 
5.4.3 Progression 
Stage (log-rank chi-square=7.4; P = 0.0250), mitotic index (log-rank chi-
square=6.3; P = 0.0124), CM (log-rank chi-square=8.6; P = 0.0034), number of 
cells above 5C (log-rank chi-square=4.3; P = 0.0387; Fig. 4, a) and 2CDI 
(log-rank chi-square=7.9; P = 0.0190; Fig. 4, b) were parameters correlating 
with progression-free survival. 
ln multivariate analyses, CM was the parameter with the highest correlation 
with progression (likelihood ratio chi-square=4.4; P = 0.0370). 
Mitotic index was the only additional parameter that contributed with borderline 
significance to the model (likelihood ratio chi-square=2.9; P = 0.0851). All other 
variables did not show a significant independent correlation (Table 5). 
72 
7. 
p 
r 
0 
g 
r 
e 
s 
s 
i 0,5 
0 0,4 
n 
f 0,3 
r 0,2 
e 
e 0,1 
0,0 
0 10 20 
DNA ANALYSIS AND BLADDER CANCER 
30 40 
months 
I (n= .. l 
II (n=Ol) 
50 60 
Figure 4a. Progression-free survival according to the number of cells above SC: I= 10 cells or 
less, ll=more than 10 cells. 
7. L 
0,9 
p 
r 0,8 
0 
g 0,7 
r 
e 0,6 
s 0,5 s 
i 
0 
0,4 
n 0,3 
f 0,2 
r 
e 0,1 
e 
0 
0 10 20 
L, 
L----, 
I 
I (n=32) 
II (n=Ol) 
'------------
30 40 
months 
III (n•ZO) 
50 eo 
Figure 4 b. Progression-free survival according to the 2C deviation index: I= $0.2, II =between 
0.2 and 2.0, Ill= ;,2.0. 
73 
DNA ANALYSIS AND BLADDER CANCER 
Table 4. Multivariate analysis of effect on survival 
Prognostic factor RR 95% CI P-value 
Histological grade NS 0.4659 
Age 1.06 (1.03, 1.10) 0.0002 
Sex NS 0.1424 
Stage Tl vs Ta 1.87 (0.84, 4.14) 
T2+ vs Ta 4.22 (1.48, 12.05) 0.0332 
Ml NS 0.3490 
2CDI 22 VS :£0.2 2.04 (0.80, 5.18) 0.0698 
RR, relative risk for covariates; Ct confidence Interval; NS, not significant; MI, mitotic index; 
2CDI, 2C deviation index 
Table 5. Multivariate analysis of the effect on Progression 
Prognostic factor RR 95% Cl P-value 
grade NS 0.1629 
Age NS 0.7429 
Sex NS 0.0838 
Stage Tl vs Ta NS 
T2+ vs Ta NS 0.1237 
Ml >5 vs :£5 2.40 (0.84, 6.87) 0.0851 
CM >46 VS ,;46 2.62 (1.04, 6.61) 0.0370 
RR relative risk for covariates; CI, confidence Interval; NS, not significant; MI, mitotic index; 
CM, modal chromosome number 
Table 6. Multivariate analysis of effect on survival in superficial TCC 
Prognostic factor RR 95% Cl P-value 
Histological grade NS 0.4002 
Age 1.06 (1.02, 1.10) 0.0012 
Ml NS 0.1017 
2CD! 0.2><2.0 vs :£0.2 1.76 (1.00, 3.09) 
>2.0 VS ,;0.2 7.63 ( 1.64, 35.57) 0.0062 
RR, relative risk for covariates~ CI, confidence Interval; NS, not significant; MI, mitotic index; 
2CDI, 2C deviation index 
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Table 7.11ultivariate analysis of the effect on Progression in superficial TCC 
Prognostic factor 
grade 
Age 
Ml 
2CDI 
>5 VS ::;5 
RR 
2.99 
95% Cl P-value 
NS 0.1629 
NS 0.9487 
(0.92, 9.70) 0.0571 
NS 0.0856 
RR, relative risk for covariates; CI, confidence Inte:rval; NS, not significant; MI, mitotic index; 
2CDI, 2C deviation index 
5.4.4 Survival and progression in superficial TCC 
In patients with superficial tumours only (Stages Ta, Tl; n=80) the same 
analyses were performed. In multivariate analyses, 2CDI (likelihood ratio 
chi-square=10.2; P = 0.0062) and age appeared to be parameters inde-
pendently correlating with survival in patients with superficial tumours 
(table 6). The presence of higher 2CDI correlated significantly with increased 
risk of death (relative risk for covariates, RR > 1). In the multivariate analyses 
of progression-free survival, mitotic index appeared to be the only inde-
pendent parameter (likelihood ratio chi-square=3.6; P = 0.0571; table 7). 
Elevated risks for progression were found in TCC patients with a high mitotic 
index (RR > 1). The 2CDI was only of borderline significance. 
5.5 DISCUSSION 
Bladder cancer has an unpredictable clinical course. The most widely used 
prognostic factors are grade and stage. Unfortunately, both lack in 
reproducibility. Using FCM, it is possible to assess DNA ploidy in bladder 
cancer as a rough measure of chromosomal content. Some studies have 
shown that there is an association between FCM DNA ploidy and clinical 
behaviour, in the sense that aneuploidy predicts which tumours will 
progress?-10 When FCM is performed on cell samples with large numbers of 
cells with a diploid DNA content and only a small number of cells with a 
higher DNA content, however, these tumours might be classified as diploid, 
and this approach therefore lacks in sensitivity 7 . The advantage of image 
cytometry as compared to FCM lies in the possibility of selectively measuring 
the DNA content of single nuclei of epithelial origin. Artifacts such as cell 
doublets or degenerated cells as well as most inflammatory and stromal cells 
can be excluded from the analyses. This justifies the interpretation of relative-
ly low numbers of very abnormal cells (DNA content higher than SC). In 
early, manually performed image cytometric studies on imprints of fresh 
tumour tissue of TCC, a correlation was found between DNA values and 
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survival in univariate analyses.l-4 In a cytometric study on 25 patients, using 
sections stained with haematoxylin and eosin, a DNA malignancy grade was 
calculated from the 2CDI. In multivariate analyses using age, tumour stage 
and tumour grade as covariate, DNA grading proved to be the only factor 
that contributed significantly to predicting survivaLS 
The advantage of automated cytometry with Leytas is that all available cells 
are subjected to image analysis, in contrast to other studies, in which only 100 
selected cells were measured.l-5 In the current study, the 2C DNA indices 
were found to be lower than reported in the study of Auffermann et al., 5 
which might be due to differences in cell selection procedures. Sti:ickle et al. 
also used automated DNA image cytometry and derived two parameters 
from the histograms (DNA ploidy and the number of cells above SC) that 
correlated well with survival in 38 patients with stages T1 to T4 TCC.6 Based 
on their results, we began the current study of 91 patients with predominantly 
low-stage tumours, using the same two parameters. In addition, the 2CDI was 
calculated. This parameter was used to arrive at a numerical expression of the 
deviation of the DNA content of the tumour cells from the mean DNA content 
of a nonproliferating diploid cell population. 
In the current study, the cytometric parameters showed a highly significant 
correlation with the modal number of chromosomes as derived from 
cytogenetic analyses and with the histopathological parameters (stage, grade 
and mitotic index). As to prediction of clinical outcome, all cytometric 
parameters showed a significant correlation with survival and progression-
free survival. The clinical relevance of these findings was tested using multi-
variate analyses with a number of other parameters that are significantly 
correlated with survival and progression-free survival (i.e., stage, grade, 
mitotic index and modal number of chromosomes). 
Our results indicate that only 2CDI has borderline significance in the predic-
tion of survival, in addition to stage and age. None of the cytometric variables 
was significant in predicting progression-free survival, whereas modal num-
ber of chromosomes and mitotic index are significant in this respect. In 
superficial TCC (Stages Ta and Tl), 2CDI appears to be a significant inde-
pendent predictor of survival and has borderline significance in the predic-
tion of progression-free survival. 
In conclusion, automated DNA image cytometry appears to be an objective 
method for grading TCC. DNA aneuploidy, high 2CDI and number of cells 
above SC are parameters correlated with aggressive tumour behaviour. In 
superficial TCC, 2CDI is an important predictor of survival. This parameter 
might be used to select a group of patients with superficial TCC that needs to 
be treated more aggressively. 
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6.1 ABSTRACT 
The potential use of numerical clu-omosomal abnormalities as predictive 
factor for the clinical behaviour of Transitional Cell Carcinoma (TCC) was 
investigated. The effect on survival and progression-free survival was 
measured in a group of 91 patients with TCC treated by transurethral resec-
tion. The survival rate of patients having tumours with a diploid 
c!u-omosomal modal number was significantly better than of patients having 
tumours with hyperdiploid chromosomal modal number. The survival rate of 
patients having TCC with diploid cells only was also significantly better than 
of patients having TCC with diploid and hyperdiploid cells. Progression-free 
survival was significantly higher in patients having TCC with a diploid 
modal number of chromosomes than in patients with a hyperdiploid modal 
number. 
Simultaneous evaluation of modal clu-omosome number or chromosomal 
range and histological grade, stage, mitotic index, age and sex as prognostic 
factors in multivariate analyses showed that the histological stage of bladder 
carcinomas is the most important factor in predicting the survival rate. In 
patients with superficial tumours (stage Ta and Tl) the modal chromosome 
number is the most important factor in predicting survival. In multivariate 
analyses concerning progression-free survival, the modal clu-omosome num-
ber appeared to be the most important factor. 
We conclude that modal clu-omosome number in TCC is useful in predicting 
survival in patients having superficial tumours (stages Ta and Tl) and in 
predicting progression-free survival in tumours of all stages. 
6.2 INTRODUCTION 
Histopathological characteristics of transitional cell carcinoma (TCC) have a 
limited predictive value for survival and progression. Therefore, other poten-
tial predictors of disease evolution have been sought. The present study was 
initiated in 1979 in search of measurable characteristics that might have 
prognostic relevance. We reported on cytogenetic analysis, 1, 2 ABH blood 
group deletion, 3 and basement membrane expression in TCC.4 In an earlier 
study an increase in modal number of chromosomes was associated with 
histological grade and stage in TCC.5 Spooner and Cooper found that well 
and moderately well differentiated tumours fell within the diploid range (42 
to 49 chromosomes), whereas the majority of poorly differentiated cancers 
showed a widespread distribution of chromosome number.S In some studies 
a large number of structural abnormalities was found, including marker 
chromosomes, especially in poorly differentiated and invasive tumours.6-10 
Low stage and low-grade carcinomas of the bladder were nearly always 
diploid or near diploid (42 to 49 clu-omosomes), although a few marker 
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chromosomes have been observed?, 8 Pauwels et al. reported on modal 
chromosome number and range in relation to progression and recurrence and 
found that marker chromosomes had no predictive value.l The range of 
chromosome number appeared to be the best predictor for invasion. 
The purpose of the present study was to determine the extent to which the 
biological potential of TCC, in terms of survival and progression-free sur-
vival, could be predicted by numerical chromosomal aberrations (modal 
number and/or range). 
We also compared our cytogenetic findings with other prognostic factors like 
stage, grade, mitotic index and age. 
6.3 MATERIALS AND METHODS 
Between January 1979 and May 1991, in 399 new patients TCC was diag-
nosed. The operation specimen of 201 of these primary TCC' s were selected 
at random by the urologist directly after the operation, without knowledge of 
stage and grade and a part of the tumour was subjected to cytogenetic 
analysis. Recognizable metaphases were found in 156 out of 201 specimens 
(78%). Most of the tumour specimens in which no metaphases were found, 
were small, showed a low-grade histology and showed no infiltration (these 
patients all showed a benign clinical behaviour). To reduce the influence of 
therapy on survival, in this study only patients undergoing transurethral 
resection (TUR) of the tumour, without any other radical therapy (radio-
therapy, cystectomy or both), were included (n~91). Clinicopathological in-
formation and TUR specimen were collected prospectively. Staging was 
carried out according to the TNM system 11 and grading (low and high-
grade), according to a slightly adapted WHO system described elsewhere.12 
Briefly, low-grade tumours are grade 1 and 2a tumours, high-grade tumours 
are grade 2b and 3 tumours. We furthermore estimated the mitotic index, 
which expresses the number of mitotic figures per 10 high power (x 40) fields 
(hpf) of neoplastic tissue.13 As criteria of counting mitoses we used the 
recommendations of Baak and Oort.14 
The mean follow-up was 36.7 months with a maximum of 122 months 
(median follow-up 30 months). Follow-up examinations were conducted at 
least semi-annually in all patients and included cystoscopy and urinary cytol-
ogy. As parameters for outcome, survival and progression-free survival were 
chosen. Progression (increase in stage and/ or the appearance of metastases) 
was assessed histologically without knowledge of previous diagnostic infor-
mation or clinical data. If a patient was lost to follow-up, survival was 
assessed by contacting municipal population registries or family doctors. 
81 
CYTOGENETICS AND BLADDER CANCER 
6.3.1 Chromosomal analysis 
For microscopic analysis of chromosomes a direct method was used as des-
cribed elsewhere in detai!.l5 Briefly, tumour samples were collected in 0.5% 
sodium citrate with 0.5 !lg/ml colcemid. After incubation for 1 hour at room 
temperature in 5 ml Hanks balanced sodium solution (Hanks BSS), the tissue 
was mechanically desegregated. Afterwards a solution of 19 ml Hanks BSS 
and 6 ml colcemid was added. After incubation for 30 min at 370C, hypotonic 
treatment in a solution of 6 ml Foetal Calf Serum (FCS) and 24 ml 0.052 M 
potassium chloride was followed by fixation in methanol-acetic acid 7: 3. 
Chromosomes were routinely stained with Giemsa. If possible C- and G-
banding was performed. 
According to the chromosome number the tumours were classified with 
regard to: a. the modal number of chromosomes (CM) into diploid (46 
chromosomes or less) or hyperdiploid (more than 46 chromosomes). b. the 
chromosomal range (CR) into tumours with cells only in the diploid range (46 
chromosomes or less) or tumours with cells also in the hyperdiploid range 
(more than 46 chromosomes). 
6.3.2 Statistical analysis 
Prognostic factors that were included in the analysis were: CM (46 or less, 
more than 46), CR (46 or less, more than 46), grade (low- versus high-grade), 
T category (stage Ta; Tl; T2+), mitotic index (less than 5 mitoses/10 hpf; 5 or 
more mitoses/10 hpf), age (less than 70 years; 70 years or more) and sex. 
Possible correlations between various prognostic factors were evaluated 
using the Pearson chi-square test. In the univariate analyses for each prognos-
tic factor Kaplan-Meier survival curves16 were analysed by means of the 
log-rank test17 with regard to time interval to death and time interval to 
progression. 
Furthermore, multivariate survival analyses were performed using Cox 
proportional hazards modeJ.l8 In these models, either CM or CR was in-
cluded together with the other factors. Age was entered as a continuous 
variable in these models. Covariates were deleted in a stepwise manner 
(backward elimination), with use of the likelihood ratio test. A P-value of 0.10 
was adopted as limit for deletion of a covariate. Of the prognostic factors that 
contributed significantly to the model, the effect was calculated in terms of 
relative risk and the associated 95% confidence interval. The survival 
analyses were performed with the BMDP statistical package (BMDP statisti-
cal software Inc, Los Angeles, CA). 
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6.4 RESULTS 
Of the 91 patients meeting our selection criteria, 71 (78%) were male and 20 
(22%) were female. Age ranged from 26 to 99 years with a mean of 74 years. 
A strong correlation was found between CM and stage (chi-square=22.4, P < 
0.0001) and between CM and grade (chi-square=20.9, P < 0.0001). The same 
was observed between CR and stage (chi-square=32.3, P < 0.0001) and be-
tween CR and grade (chi-square=21.7, P < 0.0001) (Table 1). 
Table 1. Tumour stage and grade in relation to modal number of chromosomes and 
chromosomal range in individual cells 
Chromosome number 
CM CR 
:>46 >46 :>46 >46 
Stage: Ta 36 8 25 19 
T1 12 24 1 35 
T2+ 3 8 0 11 
Grade: Low 27 3 18 12 
High 24 37 8 53 
Total 51 40 26 65 
CM, modal number of chromosomes; CR, chromosomal range 
6.4.1 Survival 
Total 
44 
36 
!I 
30 
61 
91 
CM and CR correlated significantly with survival (log-rank chi-square=12.4, 
P = 0.0004 and log-rank chi-square=6.9, P < 0.0083 respectively, fig. 1 and 2). 
Significant predictors of survival in univariate analyses were stage (log-rank 
chi-square=15.9; P < 0.0003), grade (log-rank chi-square=6.1; P = 0.0134), 
mitotic index (log-rank chi-square=5.3; P < 0.0208) and age (log-rank chi-
square=6.8; P = 0.0093). 
In multivariate analyses age (likelihood ratio chi-square=14.33, P = 0.0002) 
and stage (likelihood ratio chi-square=12.2, P = 0.0022) were the only factors 
contributing significantly to the prediction of survival (Table 2). For age the 
relative risk (RR) of dying is 1.06 (95% confidence interval [CI]; 1.03-1.09), 
which means that the risk of dying increases by 6% per year of age. The RR of 
dying of patients having stage T1 tumours versus patients having stage Ta 
tumours is 2.27 (95% CI; 1.17-4.38). The RR of dying in patients with stage T2 
(or more) tumours is 5.21 compared to patients with stage Ta tumours (95% 
CI, 1.99-13.61). 
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Figure 1. Survival according to modal number of chromosomes. 
I=CM 5 46 (n=51), II=CM >46 (n=40). 5 year survival: 1=67.2% (95% Cl; 52.5, 81.9), 
11=27.7% (95% 0; 9.2, 46.2). 
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Figure 2. Survival according to chromosomal range in individual cells. I=CR 5 46 
(n=26), II=CR >46 (n=65). 5 year survival: 1=69.0% (95% Cl; 47.6, 90.4),11=42.9% (95% 
Cl; 29.1, 56.7). 
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Table 2. Multivariate analysis of effect on survival 
Prognostic factor RR 95% Cl 
Histological grade NS 
Age 1.06 (1.03, 1.09) 
Sex NS 
Stage 
Tl vs Ta 2.27 (1.17, 4.38) 
T2+ vs Ta 5.21 (1.99, 13.61) 
Mitotic index NS 
CM NS 
RR, relative risk for covariates; CI, confidence interval; NS, not significant; CM, modal number 
of chromosomes 
6.4.3 Progression 
CM showed a significant correlation with progression-free survival (log-rank 
chi-square=8.6, P = 0.0034) (fig. 3). 
Other significant univariate predictors of progression-free survival were 
stage (log-rank chi-square=7.4; P = 0.0250) and mitotic index (log-rank chi-
square=6.3; P = 0.0124). 
The CR appeared to be only of borderline significance in this respect (chi-
square=3.4; P = 0.0670) (fig. 4). 
In multivariate analyses CM was the most important prognostic factor in the 
prediction of progression (likelihood ratio chi-square=4.4, P = 0.0370) (Table 
3). The risk of progression for patients having hyperdiploid tumours is 2.62 
higher than for patients having diploid tumours (95% CI; 1.04, 6.61). 
Mitotic index was the only additional factor that contributed borderline sig-
nificantly to the model (likelihood ratio chi-square=2.9, P = 0.0851) (Table 3). 
All other variables did not show a significant independent prediction. 
6.4.4 Patients with superficial tumours 
In patients with only superficial tumours (stage Ta, Tl) (n=80) similar 
univariate and multivariate analyses were performed. In multivariate 
analyses CM is (next to age) the only independent factor in predicting sur-
vival in patients with superficial tumours (RR= 2.4; 95% CI: 1.22, 4.66). In 
predicting progression-free survival CM appears to be the only independent 
factor (RR=3.26 with 95%CI 1.36, 8.49) in the multivariate analyses. 
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Figure 3. Progression-free survival according to modal number of chromo-
somes. l=CM,; 46 (n= 51), ll=CM >46 (n=40). 5 year progression-free survival: 
1=82.2% (95% Cl; 69.9, 94.5), ll=54.5% (95% CI; 33.6, 75.4). 
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Figure 4. Progression-free survival according to chromosomal range in in-
dividual cells. I=CR ,; 46 (n=26), ll=CR >46 (n=65). 5 year progression-free 
survival: 1=87.9% (95% CI; 75.0, 100), ll=63.8% (95% CI; 49.7, 78.9). 
CYTOGENETICS AND BLADDER CANCER 
Table 3. Iviultivariate analysis of the effect on progression 
Prognostic factor 
grade 
Age 
Sex 
Stage 
T1 vs Ta 
T2+ vs Ta 
Mitotic index 
::;;5 VS <5 
CM 
RR 
2.40 
2.62 
95% CI 
NS 
NS 
NS 
NS 
NS 
(0.84. 6.87) 
(1.04, 6.61) 
RR, relative risk for covariates; CI, confidence interval; NS, not significant; CM, modal number 
of chromosomes 
6.5 DISCUSSION 
Bladder cancer has an unpredictable clinical course. The most widely used 
prognostic factors are grade and stage. Unfortunately both have their 
problems in reproducibility. Using flow cytometry (FCM) it is possible to 
assess DNA-ploidy in bladder cancer as a rough measure of chromosomal 
content. Some studies have shown that there is an association between DNA-
ploidy and clinical behaviour, in the sense that aneuploidy is a feature which 
predicts which tumours will progress.19-22 However, when FCM is per-
formed on cell samples with large numbers of cells with a diploid DNA 
content and only a small number of cells with a higher DNA content, these 
tumours might be classified as diploid19 and this approach therefore lacks in 
sensitivity. Karyotyping is another possibility. Specific chromosomal aberra-
tions of chromosome 1, 7, 9, 11 and 17 have been described using convention-
al cytogenetic and chromosome specific in situ hybridization studies.23, 24 As 
yet the number of patients in these studies is too small and follow-up times 
are too short to assess the clinical relevance of these findings. Numerical 
abnormalities in TCC are rather simple to establish when analyzable 
meta phases can be obtained in a tumour (in 78% of our specimen), in contrast 
to full karyotyping which is a much more complicated procedure. In search 
of additional prognostic factors we therefore studied the clinical relevance of 
numerical chromosomal abnormalities. 
With regard to the prediction of clinical outcome we have shown that patients 
with diploid tumours have a significantly longer survival (5-year survival 
67.2% versus 42.9%) and progression-free survival (5-year progression-free 
survival82.2% versus 54.5%) than patients with hyperdiploid tumours. 
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Our material was also analysed for additional, potentially useful prognostic 
factors. Stage, grade and mitotic index were found to have significant correla-
tion with overall survival and progression-free survival (age only had sig-
nificant correlation with survival). Multivariate analyses were performed and 
the possible additional value of CM in predicting clinical outcome was 
evaluated. Our results indicate that of all the prognostic factors, stage and age 
are the most important independent predictors of overall survival (Table 2). 
With regard to progression-free survival, CM appears to be the most impor-
tant predictor (Table 3). 
In superficial TCC (stage Ta and Tl) CM and age are the only independent 
predictors of survival in multivariate analyses. ln this group of patients CM 
appeared to be the only factor with predicting value for progression-free 
survival. 
In conclusion, tumour stage appears to be the most important indicator for 
overall survival in TCC. Our findings suggest that CM may be an important 
factor to predict progression, in terms of more aggressive behaviour of TCC, 
independent of stage and grade. CM could be of help to establish more 
effective treatment protocols for this disease. 
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7.1 ABSTRACT 
Thirty TCC's of the bladder were examined by classical chromosome count-
ing to establish range, modal number and percentage of meta phases with 2n, 
3n, 4n and ~5n chromosomes. In addition fluorescence in situ hybridization 
(FISH) was applied to interphase nuclei to detect the percentage of tumour 
cells showing polyploidization and chromosome imbalance. In FISH 
centromere specific DNA probes for chromosomes 1, 7, 9, and 11 were used. 
The tumours were analysed flow cytometrically to determine the DNA index 
(DI). 
Fourteen out of 21 cases (67%) having a DI = 1 showed, after classical 
chromosome counting, in addition to a diploid modal number, some cells 
with a 3n and 4n chromosome count. With FISH 8 cases (38%) showed a low 
percentage of cells with multiple signals for each of the probes, thus indicat-
ing polyploidization. In 13 (62%) cases an imbalance between different 
chromosomes was detected. In 9 tumours, having a DI of 1.6 to 1.9, classical 
chromosome counting showed low percentages of ~5n cells in 4 cases, in 
addition to a triploid modal number. With FISH in 6 cases a low percentage 
of cells showed five or more signals for each of the chromosomes, indicating 
polyploidization. In all the cases a chromosome imbalance was detected. 
With classical chromosome counting not all tumours can be analysed. With 
FISH small percentages of polyploid cells are not recognized. Both methods 
complement each other in that chromosome counting allows readier detec-
tion of heterogeneity in DNA-diploid tumours after polyploidization, 
whereas FISH allows efficient recognition of the chromosomes involved in 
the process of imbalance. 
7.2 INTRODUCTION 
Transitional cell carcinomas (TCC' s) of the bladder comprise a heterogeneous 
group of tumours. Apart from the heterogeneity that is observed for 
specimens of a defined histopathological category, an intra-lesional 
heterogeneity also exists. Heterogeneity may explain differences in the be-
haviour of tumours with identical classifications) 
With respect to prognostic parameters, in addition to histopathological char-
acteristics, DNA content, 2-4 as well as cytogenetic data, obtained on the basis 
of classical metaphase spreadsl or interphase cytogenetics, 4, 5 are mentioned 
as useful predictors. Flow cytometric detection of the DNA content has, 
however, the disadvantage that small variations in DNA content cannot be 
detected. Karyotyping of bladder cancers to assess numerical and structural 
chromosomal defects, is not always successful due to limitations of the cancer 
specimen, such as small number of metaphases, the quality of the 
chromosomes, the complexity of the karyotypes and in case of culture, a 
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selection of cell types.6, 7 However, the evaluation of the chromosome num-
ber in a few dozens of tumour cells can still give relevant information. In such 
studies the presence of some hyperdiploid cells, among predominantly 
diploid ones, is found much more frequently in invasive than in non-invasive 
bladder tumours.l• 8 lntra-lesional heterogeneity can also be analysed by 
fluorescence in situ hybridization (FISH). FISH, also called interphase 
cytogenetics, allows the analysis of several hundreds of (tumour) cells, with 
many different DNA probes. As a result the detection of minor cell popula-
tions, as well as an imbalance in chromosome copy numbers within one 
tumour has become possible.4Jn a recent study it appeared that in 14 out of 
24 flow cytometrically diploid, non-invasive ICC's, an imbalance between 
chromosome copy numbers was detected. In addition to this imbalance, 3 out 
of 24 cases showed a considerable amount of cells with multiple copies for 
several chromosomes, suggesting polyploidization.4 This process has also 
been described for other solid tumours.9, 10, 15 
This study was undertaken to detect intra-tumoral heterogeneity by classical 
chromosome counting and by FISH, in bladder tumours having a diploid or 
a hyperdiploid DNA content. 
7.3 MATERIALS AND METHODS 
7.3.1 Tumour !issue samples 
Thirty cases of unfixed fresh TCC's were mechanically desegregated as 
described before12 and the cell suspensions were used to determine 
chromosome counts in at least 20 cells. FISH was applied as well on these 
samples for 4 chromosomes. The DNA content was established flow 
cytometrically. Staging was done according to the TNM classification and 
grading according to a modification of the WHO system11 
7.3.2 Classical chromosome counting 
For microscopic chromosome analysis a direct method has been used as 
described earlier12 The percentage of meta phases of a defined tumour being 
diploid (2n = 46 ± 11), triploid (3n = 69 ± 11) and so on is calculated. 
Chromosomal range and modal number are determined as well. 
7.3.3 Fluorescence in situ hybridization (FISH) 
200 cells were evaluated after application of centromere specific probes for 
chromosomes 1, 7, 9 and J14, 13 Aberrations in the chromosome numbers 
were expressed in terms of tetraploidization, polyploidization and 
chromosome imbalance. 
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Figure 1. C-banded metaphase (a) and FISH for chromosome 1 (b-i) of case nr. 30 
a Arrows indicate heterochromatine, probably of chromosome 1. Double arrow indicates 1q+; 
b FISH in a metaphase of this TCC after DAPI staining. Arrows indicate heterochromatin 
staining based on preferential AT staining by DAPI (double arrow indicate 1q+ ); c FISH signals, 
after using a probe for the heterochromatin; d, e FISH in interphase nuclei showing 
heterogeneity in copy numbers; f, g Polyploidization (>Sn) shown by FISH in a metaphase 
after DAPI staining. Two copies of 1q+ indicate polyploidization; h, i Interphase nucleus 
stained with DAPI (h) and after FISH (i) showing multiple copies for chromosome 1. 
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In case of tetraploidization four fluorescent signals were observed for all the 
probes used, in a significant part of the cells above a certain threshold value 
set based on criteria summarized before.4, 13, 16 Among these criteria are the 
low percentages of multiploid cells detected in normal epithelium of the 
urinary bladder. In this series of experiments a cell population was indicated 
as tetraploid/polyploid when more than 3-7% of the total cell population 
contained a duplicated number of FISH signals. The threshold level is de-
pendent on nuclear morphology, cell clumping, an even distribution of DNA 
staining in the nuclei, discreetness of FISH signals and the percentage of cells 
with no FISH reactivity. In the diploid tumours, most cells showed two 
signals for the individual chromosomes. 
Polyploidization was considered real when a fraction of cells above the 
arbitrary threshold showed ~ 5 signals for all the probes used. In the 
triploid/tetraploid tumours, most cells showed 3 or 4 signals for the 
chromosomes tested. 
Chromosome imbalance is defined as a difference in the number of signals for 
individual chromosomes detected with the probes used. For instance a single 
signal for chromosome 9, three signals for chromosome 7 and two signals for 
chromosome 1 and 11, in a significant percentage of cells of the tumour, is 
interpreted as an imbalance. This particular pattern would thus show an 
underrepresentation of chromosome 9 and an overrepresentation of 
chromosome 7. 
Intra-tumoral heterogeneity is expressed in case of chromosome imbalance 
and/ or tetra- or polyploidization, as determined by FISH. 
Heterogeneity is also expressed when cells have a ploidy count deviating 
from the modal ploidy count as determined by classical chromosome count-
ing. 
7.3.4 Flow Cytometry (FCM) 
The FCM procedure was described in detail before.6, 14 Briefly, the samples of 
mechanically desegregated cells were stained with propidium iodide (PI) for 
DNA estimation. Cell analysis was performed using a cytofluorograph SOH 
(Ortho Instruments, Westwood, MA). PI was excited at 488 nm with an argon 
ion laser. Fluorescence was measured using a 630 nm filter. Chicken red blood 
cells were used as an internal standard, while human lymphocytes were used 
as an external standard. Samples with a Dl of 1 ± 0.12 were interpreted as 
normal diploid. 6 
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7.4 RESULTS 
7.4.1 DNA-Diploid tumours (n=21) 
Fourteen tumours out of 21, with a Dl = 1, revealed triploid (3n) and/ or 
tetraploid (4n) cells by means of classical chromosome counting (table 1). 
Heterogeneity was thus detected in 67% of the tumours. 
After FISH, 8 tumours (38%) showed tetraploidization. Imbalance of 
chromosomes was seen in 13 (62%) cases in which a loss or gain of 
chromosomes was detected. The chromosomes involved were presented ear-
!ier.4 When the aberrant cases showing tetraploidization and/ or imbalance 
were combined, 14 out of 21 cases (67%) showed intra-lesional heterogeneity. 
Table 1. Summary of the data of 21 patients with DNA diploid TCC's. 
nr age stage grade chromosomes FISH 
%cells with 
range mn 2n 3n 4n tet imb 
I 74 pTa G2b 40-83 44 95 5 + 
2 68 pTI G2b 40-90 43 77 10 13 + + 
3 80 pTI G2b 38-49 46 100 
4 68 pTa G2b 39-65 45 98 2 
5 76 pTa G2b 42-87 46 67 33 + 
6 73 pTa G2a 45-46 46 100 
7 50 pTa G2a 43-46 46 100 + 
8 63 pTa G2b 45-46 46 100 
9 78 pTa G2b 42-100 46 90 10 
10 65 pTa G2b 46 46 100 + + 
11 53 pTa G2b 45-90 46 96 4 + 
12 78 pTa G2b 46-90 46 84 16 + + 
13 72 pT2 G2b 35-65 46 95 5 
14 61 pTa G2b 46-100 47 94 6 + + 
15 78 pTa G2a 46 46 100 
16 66 pTa G2a 45-46 45 100 + 
17 63 pTI G2b 36-90 43 94 6 + 
18 56 pTa G2b 42-80 44 68 32 + + 
19 74 pTa G3 42-90 46 86 14 + + 
20 71 pT2 G3 37-80 42 84 8 8 + + 
21 70 pTI G2b 37-85 46 97 3 + 
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Table 2. Summary of data o£9 patients with DNA aneuploid TCC (Dl1.6- 1.9) 
nr age stage grade chromosomes FISH 
%cells with 
range mn 2n 3n 4n ~5n poly imb 
22 64 T2 G3 66-69 69 100 + + 
23 90 T2 G3 55-65 65 10 90 + + 
24 80 Ta G2b 60-120 69 88 12 + 
25 66 T1 G2b 47-69 62 23 77 + 
26 41 T1 G2b 75-140 80 95 5 + + 
27 60 T3 G2b 48-80 75 7 93 + + 
28 91 T2 G3 45-78 70 7 93 + 
29 65 T2 G2b 65-130 75 97 3 + + 
30 72 Tl G3 50-250 70 3 92 5 + + 
poly = polyploidization 
A considerable overlap was noticed between the cases with tetraploidization 
as detected by FISH and the cases with 3n and or 4n cells as detected by 
classical chromosome counting. Seven out of eight cases having four fluores-
cent signals also had cells with a 3n and or 4n chromosome count. In one case 
(nr 10) no numerical aberration was found using classical cytogenetics, 
whereas FISH showed an imbalance as well as tetraploidization. 
Comparing chromosome counting and FISH with regard to their feasibility to 
detect (near-) tetraploid cells, classical chromosome counting gave a better 
score than FISH. 
7.4.2 DNA-Aneuploid tumours (n=9) 
Eight tumours out of 9, with a DI= 1.6-1.9 revealed 2n and/ or ~ 5n cells by 
means of classical chromosome counting (table 2). Heterogeneity was thus 
present in 89% of the tumours. In 4 of these cases one or more~ 5n cells were 
found. All cases showed a triploid modal chromosome count. 
After FISH 6 out of 9 cases (67%) showed polyploidization and all cases 
showed chromosome imbalance. Thus, heterogeneity was detected in all 
tumours. One example is given in Fig 1. 
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7.5 DISCUSSION 
Tetraploidization is a generally accepted step in the process of tumour 
progression and accepted as an indicator of poor prognosis when cells, result-
ing from this process are detected in a malignant disease.4, 10, 15 For recogni-
tion of tetraploidization by means of classical cytogenetic procedures, 
metaphases are needed. However, dividing cells may be scanty in solid 
tumours; in our hands the metaphase frequency in well-differentiated TCC' s, 
without previous culture, amounts to a few odd usable metaphases between 
about 10.000 non-dividing or non-metaphase cells per slide. In normal blad-
der tissue the metaphase frequency is even lower. Hence, (nearly) all 
metaphases originate from tumour cells. This means that for analysis of 20 
meta phases at least 100.000 cells must be checked. Earlier studies have shown 
that the analysis of 200 interphases by means of FISH could be performed in 
a routine setting.4, 16, 17 However, the risk exists that abnormal cells, when 
present in low frequencies, are missed as a result of large amounts of normal 
epithelial or stromal cells. Analysing more than 200 cells per sample without 
computer help, is difficult to do. Moreover, it is open to discussion whether 
more information can be gathered by counting more than 200 cell.s from 
clinical material, on account of the threshold level. In stimulated lymphocytes 
from a healthy donor, up to 2% of the cells were identified as having three or 
four signals and 10% showed only one signal for the probes of chromosomes 
1, 7, 10 and 18 used.l8 In bladder tumour material it appeared that up to 3% 
of the cells did not react with the probes and up to 10% of the cells of diploid 
tumours showed one, three or four signals with the probes for chromosomes 
1, 7, 9 and 11. The aberrant copy number must therefore exceed a certain 
threshold before being interpreted as abnormal. Such thresholds depend on 
the quality of the FISH procedure, the presence of split spots, morphology of 
nuclei or signal intensities.4, 13 For the analysis of polyploidization a high 
quality of the cell preparations is required.4 For classical cytogenetics stand-
ard tables at different confidence limits, specific to the problem of presence or 
absence of mosaicism in a cell sample, are available.l9 For FISH such tables 
are not yet available. 
Comparing the power of classical chromosome counting with the FISH pro-
cedure for the detection of heterogeneity in tumour cell populations, it ap-
peared that FISH could not recognize most cases in which the percentage of 
3n/4n cells was under 10%. On the other hand, in 13 out of 21 DNA-diploid 
cases a chromosome imbalance was detected with FISH. However, in inter-
preting these differences in the sensitivity of both methods, it has to be kept 
in mind that classical chromosome counting is based on the analysis of 
dividing cells and that no information is obtained about non-dividing cells. 
Therefore, FISH procedures are non-selective, in contrast to the classical 
chromosome counting procedure. This may explain some of the discrepancies 
between these methods. 
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Invasive tumours (pT1-pT3) more frequently showed one or more hyper-
diploid cells as compared to non-invasive lesions.! 
It has been reported that during tumour progression chromosomal deletions 
precede the process of tetraploidization.4, 10 As examined previously, in 
about 40% of superficial tumours chromosome 9 was lost. 
It may therefore be of clinical importance to detect the deletion and the 
following tetra- and polyploid cells as early as possible in the course of the 
disease. 
The tumours with a Dl between 1.6 and 1.9 all showed a modal chromosome 
count of 3n. In 4 out of 9 cases ;, 5n metaphases were also detected, whereas 
by FISH in 6 out of 9 cases polyploidization was observed. The problem with 
chromosome counting is that, generally, chromosome counts in the hexaploid 
region show so many overlaps that counting is arbitrary. With FISH, the 
evaluation of such cells can be done more successfully. 
It is striking that all 9 cases showed a near triploid modal chromosome 
number (mean 70.5), whereas a tetraploid number was expected. 
Tetraploidization is probably followed by loss of chromosomes as a result of 
progression. A similar situation was described for colorectal tumours, where 
a mean chromosome number of 71.5 was described in 23 cases.IO The biologi-
cal implications of polyploidization for tumour evolution are still unknown. 
The flow cytometric estimation of the DI, as used in this study, could not 
detect low frequencies of tetraploid and polyploid cells. The presence of 
variable admixtures of non-epithelial, non-tumour cells may be one of the 
reasons. To eliminate these cells, labelling for cytokeratins has been sug-
gested. However a substantial alteration of the DI was not obtained in the 
past.6 
Classical chromosome counting is not always successful. In our hands, about 
65% of non-invasive TCC specimens provided us with enough metaphases 
for numerical analysis. Heterogeneity was detected in 67% of DNA-diploid 
and 89% of DNA-hyperdiploid cases after chromosome counting. FISH could 
be applied successfully in more than 90% of the tumours. This latter proce-
dure however has limitations with respect to the threshold and the restricted 
number of DNA probes that can be applied in a routine setting. Heterogeneity 
was detected in 38% of DNA-diploid cases regarding tetraploidization and in 
67% of the cases regarding imbalance. In DNA-hyperdiploid tumours in 67% 
of the cases heterogeneity was seen as polyploidization by FISH and in 100% 
as chromosome imbalance. Both methods complement each other in the sense 
that cl1romosome counting allows a better detection of heterogeneity after 
polyploidization, whereas FISH allows the characterization of the specific 
chromosomes involved in the process of imbalance. 
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GENERAL DISCUSSION 
8.1 INTRODUCTION 
The majority of patients who develop Transitional Cell Carcinoma (TCC) of 
the urinary bladder are between the ages of 50 and 70. Especially in the older 
age groups, the disease does not significantly affect the overall survival of 
these patients.l These patients seem to be at such low risk of dying from the 
tumour, that overtreatment should be avoided. In some patients the TCC 
progresses rapidly and these patients may die form this cancer. For the 
clinical management of TCC therefore, methods are necessary that accurately 
predict the behaviour of the tumour in individual patients at an early stage of 
the disease process. In this final chapter we will discuss the results of the 
studies, aimed at defining such parameters, from a more general point of 
view. 
8.2 HISTOPATHOLOGICAL FACTORS 
8.2.1 Histopathological Staging 
Clinical tumour staging is based on cystoscopy, bimanual palpation and 
echoscopy. However the most exact and objective method is histopathologi-
cal staging. Of course, also histopathological staging has its problems.2 The 
biopsy material should be representative for the tumour and should contain 
all layers of the bladder wall. In superficial TCC the pathologist has to 
differentiate between Ta and Tl TCC, also in case of micro-invasion. Base-
ment membrane (BM) immunostaining can be of help in some cases to distin-
guish these superficial stages, as was described in chapter 3. Also muscle 
invasion is an important prognostic sign. In some tumours a considerable 
fibromuscular reaction is seen underneath the tumour. Invasive growth be-
tween these structures should not be considered as muscular invasion. BM 
immunostaining can be of help in finding small groups of tumour cells 
between muscle fibres because smooth muscle fibres show a distinct BM. 
Pathological stage is a very important single prognostic parameter, also in 
superficial TCC there is a clear difference in progression and survival be-
tween stage Ta and Tl tumours (chapter 2-6). 
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8.2.2 Histopathological Grading 
All systems of grading distinguish one or several intermediate grades in 
addition to low and high-grades as extremes.3-8 The most frequently used 
grading system is that of the World Health Organisation (WHO).S The criteria 
used for determining anaplasia in this system are rather vague. As shown by 
others9, 10 as well in our own study (chapter 2), the interobserver 
reproducibility in grading TCC is only about 60% in this system. Further-
more, WHO grade II tumours appear to be heterogenous, as is shown in 
chapter 4 by morphometric analysis and comprise low- and high-grade 
tumours. Jordan et al. designed a system in which WHO grade I tumours are 
classified as papilloma and the other tumours as either low-grade or high-
grade? Even then a few intermediate grade tumours did not fit into either 
group. These authors also stated that a considerable interobserver variation 
could be expected due to the many variables used. In the grading system we 
described in chapter 2, only three variables were used: epithelial thickness, 
nuclear polarity and pleomorphism, resulting in a high interobserver agree-
ment (80% of the tumours were correctly graded by different pathologists). 
The high interobserver agreement would be an advantage in comparing 
results of therapy and for epidemiological studies. The described low-high 
grading appeared to be a significant single predictor of survival and progres-
sion. The survival of patients with low-grade tumours was significantly better 
than that of patients with high-grade tumours. The progression-free interval 
was also significantly longer in patients with low-grade tumours than in 
patients with high-grade tumours. 
8.3. BASEMENT MEMBRANES 
It is a generally accepted concept, that invasion of a carcinoma involves the 
degradation and penetration of the subepithelial BM. This phenomenon 
might be used for histopathological evaluation of neoplasms of the bladder. 
Conventional staining techniques for visualisation of the BM, like reticulin 
silver impregnation and PAS staining, are not specific for BM alone.ll Other 
structures are stained at the same time. lrnmunostaining techniques, using 
antibodies specific for collagen type IV and laminin, allow visualization of 
specific BM constituents.l2-21 The study of the BM in TCC is simplified by this 
technique. TCC's show various amounts of BM structures. Some TCC's show 
a continuous BM, some show a patchy BM and others show no BM structures 
at all. As is shown in chapter 3 the BM pattern as a single prognostic factor 
conveys significant information. We did find a significant correlation be-
tween tumour stage and BM staining. A correlation was also found between 
ploidy and BM staining, as well as between histological grade and BM stain-
ing pattern. 
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Survival could be predicted significantly, however progression could only be 
predicted borderline significantly. We found no relation between the 
presence or absence of BM structures and recurrence rate. BM visualization 
by immunohistochemical techniques can facilitate recognition of tissue ar-
chitecture. As such this technique is of importance in the demonstration of 
microinvasion in superficial TCC and in demonstrating muscle invasive 
growth. 
8.4 NUCLEAR MORPHOMETRY 
High-grade tumours are characterized by larger nuclei and more variation in 
nuclear size.22 By morphometry, measurement of individual nuclei is easily 
performed on histological slides with high accuracy.23 The methods of mor-
phometry are relatively simple and reproducible.9, 24 We ap:olied a simple 
technique of morphometric grading to test whether it could divide TCC in 
low- and high-grade malignant tumours.25[n chapter 4 the clinical relevance 
of morphometry is described. Tumours with relatively small nuclei appeared 
to have a significantly better clinical behaviour in respect to survival and 
progression than tumours with large nuclei. Morphometry could be especial-
ly useful when the WHO system of grading is used, because by nuclear size 
WHO grade ll tumours can be divided in two groups of TCC, with sig-
nificantly different clinical behaviour. Patients with WHO grade II tumours 
with relative small nuclei have a significantly better prognosis than patients 
with WHO grade II tumours with large nuclei. 
The counting of mitotic figures in a histological section has been described as 
a useful diagnostic procedure, yielding prognostic information.26-28 The 
counting of mitoses can be highly reproducible when a standardized method 
is used as was shown in a large multicenter study.29 The mitotic index was 
used as a separate prognostic factor in our analyses, as described in the 
chapters 2 to 6. The mitotic index appears to be an important single prognos-
ticator in respect of survival and progression. Patients having TCC with a low 
mitotic count have a better prognosis than patients with a high number of 
mitosis in their tumour. 
8.6 DNAANALYSIS 
The clinical use of the measurement of nuclear DNA content in TCC has been 
described in many papers.30-46 Many of the studies in this field describe flow 
cytometry (FCM) as a method to determine DNA ploidy and stress the clinical 
relevance of this method.30-37 FCM has the advantage that it can rapidly 
measure many cells but it has the disadvantage that tumours with 
predominance of cells with a diploid DNA content and only very few cells 
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with a high DNA content, might be classified as diploid. The image cytometry 
method that is described in chapter 5 has the additional value that the DNA 
content of individual cells can be measured and that all cell images are stored 
in computer files, which allows visual control of the measured nuclei. The 
parameters we calculated from DNA cytometric analyses and used for statis-
tical evaluation of their prognostic value were: ploidy class, the number of 
cells exceeding SC and the 2C deviation index (2CDI). There was a significant 
difference in survival between DNA image cytometrically determined 
diploid and non-diploid cases. The presence of nuclei with a high DNA 
content indicated poor prognosis. The 2CDI was also an indicator of survival. 
Image cytometrically determined factors were also found to be strong predic-
tors of progression-free survival. 
8.7 CYTOGENETIC ANALYSIS 
In chapter 6 and 7 "classical" metaphase and "modern" interphase 
cytogenetic analyses are described. In the classical cytogenetic analysis 
chromosomes are identified in the metaphase of the cell cycle. Numerical and 
structural abnormalities can be recognized. The disadvantage of the method 
is that it can be only be performed on fresh tumour tissue. Furthermore, 
sampling may be a problem because not all the tissue can be used for 
chromosome analysis and only a fraction of the cells will yield analyzable 
metaphases. Interphase cytogenetics allows assessment of numerical and 
structural chromosome abnormalities through the use of probes which 
specifically bind to chromosome specific DNA sequences in the chromosomal 
centromeric region.47-52 This technique can be applied on fresh tumour 
samples47-50 but also on routinely processed paraffin sections.51, 52 As is 
described in chapter 6, with the classical chromosome counting enough cases 
were analysed to allow testing for clinical relevance of the method. The 
parameters derived from chromosome counting include the range of the 
number of chromosomes in different metaphases and the modal number of 
chromosomes in all cells counted. Both parameters appear to have significant 
prognostic impact. The survival rate of patients having tumours with a 
diploid chromosomal modal number was significantly better than that of 
patients having tumours with a hyperdiploid chromosomal modal number. 
The survival rate of TCC patients with diploid cells only, was also significant-
ly better than of patients having TCC with diploid and hyperdiploid cells. 
Progression-free survival was significantly higher in patients having TCC 
with a diploid modal number of chromosomes than in patients with a hyper-
diploid modal number. 
The fluorescence in situ hybridization (FISH) method was applied successful-
ly on more than 90% of the TCC tissue samples, compared with a success rate 
of about 75% for the classical cytogenetic method. In chapter 7 the results of 
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classical cytogenetic analysis are compared with those of interphase 
cytogenetics using probes for chromosomes 1, 7, 9 and 11. With regard to their 
feasibility to detect (near-) tetraploid cells between predominantly diploid 
cells, chromosome counting in metaphases gave a better score than FISH in 
tumours with a FCM diploid DNA index. The presence of small percentages 
of tetraploid or polyploid cells is interpreted as an indicator of progression. In 
tumours aneuploid by FCM, intralesional heterogeneity could be detected 
better by FISH than by means of the classical method. Both methods comple-
ment each other in the sense that chromosome counting allows better detec-
tion of heterogeneity following tetra- or polyploidization, whereas FISH 
allows the characterization of the specific chromosomes involved in the 
process of imbalance. 
8.8 MULTIVARIATEANALYSIS 
In the chapters 2 to 6 multivariate analysis is applied in order to evaluate the 
relative contributions of the tested parameters to the prediction of prognosis. 
Several parameters were found to be significant single prognostic indicators 
of survival and progression. Between all these parameters strong correlations 
were invariably found. 
To eliminate the effect of correlation between parameters multivariate 
analysis can be applied successfully.37, 53-56 
In a multipararneter model with the tested parameters stage, grade, BM 
content, chromosomal counting, morphometric factors and cytometric 
parameters, stage always proved to be the most important factor. Because of 
the strong correlation between different parameters most other parameters 
could not add much to the prediction of survival and progression. The only 
parameters that had additional value were mitotic index, 2C-deviation index 
and modal number of chromosomes, especially in the prediction of progres-
sion. These parameters could be used in TCC patients to plan the therapeutic 
strategy. However it is evident that in individual patients the behaviour of 
TCC ca1mot be predicted by single parameter or even by multiparameter 
analysis. If a patient has for instance a superficial TCC, a high mitotic count 
can still be the main factor that determines a bad prognosis. 
8.9 THE FUTURE 
The ongoing developments in the molecular biology of cancer will deepen 
our understanding of the process of oncogenesis. New techniques, developed 
on the basis of the results of fundamental research, such as the interphase 
cytogenetics, could prove to be of clinical importance. Specific chromosome 
aberrations, numerical or structural, could valuable for the prediction of 
107 
GENERAL DISCUSSION 
survival, progression and recurrence in TCC. Interphase cytogenetic analysis 
could be combined with more conventional techniques including light 
microscopy, morphometry, DNA cytometry and blood group deletion assay 
to develop powerful prognostic algorithms. Ideally one should ultimately 
find a combination of variables that can distinguish tumours with an aggres-
sive and those with a relatively benign nature. The nature of the multistep 
and multifactorially determined process of carcinogenesis, however, renders 
it unlikely that parameters will be found, which distinguish patients with 
absolute certainty. 
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SUMMARY 
In this thesis a study of objective and reproducible characteristics, that might 
have prognostic significance in bladder cancer, is described. In the Nether-
lands bladder cancer is fourth in the order of frequency in the occurrence of 
tumours in males. In females bladder cancer is less frequent (twelfth most 
frequent). The male-female ratio is 4.8 to 1. In other countries the male 
predominance is less pronounced. The most used parameters in the manage-
ment of bladder cancer are stage and grade. However reproducibility 
problems are well known from the literature. We have described a grading 
system for bladder cancer in which only low-grade and high-grade malignant 
tumours are distinguished. Reproducibility proved to be good. The survival 
of patients with low-grade tumours was significantly better than that of 
patients with high-grade tumours. The progression-free interval was also 
significantly longer in patients with low-grade tumours than in patients with 
high-grade tumours. 
Penetration of the basement membrane (BM) was studied by immunohis-
tochemical staining of some BM components. The survival rate of patients 
having tumours with an interrupted or absent BM was significantly lower 
than that of patients having tumours with an intact BM. The rate of progres-
sion was greater in tumours with an interrupted or absent BM than in 
tumours with an intact BM. No association was found between BM status and 
recurrence. 
Selective nuclear morphometry was used as a quantitative measure of nuclear 
grade. In WHO grade II (histological grading) tumours morphometric 
heterogeneity could be demonstrated. There was a significant difference in 
survival between morphometrically determined low-grade malignant cases 
and high-grade malignant cases, the presence of large nuclei indicating poor 
prognosis. The morphometrically determined grade was also found to be a 
strong predictor of tumour progression. 
DNA content of nuclei was studied by DNA image cytometry. By image 
cytometry the DNA content in individual cells is measured. This method is 
more sensitive in determining ploidy than flow cytometry, especially in 
tumours with a low number of aneuploid cells. There was a significant 
difference in survival between DNA image cytometrically determined 
diploid and non-diploid cases. The presence of nuclei with a high DNA 
content indicated poor prognosis. The 2C deviation index (2CDI) was also an 
indicator of survival. Image cytometrically determined factors were also 
found to be strong predictors of progression. We also investigated the poten-
tial use of numerical chromosomal abnormalities as predictive factor for the 
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clinical behaviour of TCC. The survival of patients having tumours with a 
diploid chromosomal modal number was significantly better than of patients 
having tumours with hyperdiploid chromosomal modal number. Progres-
sion was seen more frequently in patients having TCC with a hyperdiploid 
modal number of chromosomes. 
Chromosome counting in metaphase nuclei was compared with fluorescence 
in situ hybridization (FISH). In FISH centromere specific DNA probes for 
chromosomes 1, 7, 9, and 11 were used. 
Both methods complement each other in that sense that chromosome count-
ing allows better the detection of heterogeneity after tetra- or polyploidiza-
tion, while FISH allows the detection of the involvement of specific 
chromosomes in karyotypic abnormalities. With classical chromosome count-
ing not all tumours can be analysed. With FISH small numbers of cells with 
tetra- or polyploidization, between many diploid cells, are not recognized. 
Combining multiple parameters from our studies, stage appeared to be the 
most important prognostic factor in all our studies. The mitotic index ap-
peared to be a factor that has independent value in predicting progression. In 
superficial bladder cancer the modal chromosome number and one of the 
cytometrically determined factors (2CDI) appeared to be important 
parameters in predicting survival and progression. FISH on interphase nuclei 
has to be further investigated regarding its clinical value. 
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SAMENVATTING 
In dit proefschrift wordt een onderzoek beschreven naar objectieve en repro-
duceerbare kenmerken van blaaskanker die mogelijk betekenis hebben voor 
de prognose. In Nederland is blaaskanker de vierde meest voorkomende 
kwaadaardige tumor bij mannen. Bij vrouwen komt blaaskanker minder voor 
(twaalfde plaats). Bij mannen komt blaaskanker 4.8 maal zo veel voor als bij 
vrouwen. In andere land en is het verschil tussen mannen en vrouwen minder 
duidelijk. De meest gebruikte parameters voor het tumor gedrag bij de behan-
deling van blaaskanker zijn stadium en graad. Echter uit de literatuur is 
bekend dat er problemen bestaan met de reproduceerbaarheid van het vast-
stellen van deze parameters. Wij hebben een graderingssysteem voor blaas-
kanker beschreven waarbij aileen laag- en hooggradig kwaadaardige 
tumoren worden onderscheiden. De reproduceerbaarheid bleek goed te zijn. 
Patienten met laaggradige tumoren Ieven significant Ianger dan patienten 
met hooggradige tumoren. 
Het doordringen van de basaalmembraan werd bestudeerd door immuun 
histochemische kleuring van enkele basaalmembraan componenten. Bij pa-
tienten waarbij in de blaastumor de basaalmembraan onderbroken of afwezig 
was, bleek de overleving significant korter dan bij patienten met een tumor 
waarvan de basaalmembraan intact was. Ook was de progressievrije periode 
van patienten met een tumor waarvan de basaalmembraan onderbroken of 
afwezig was korter dan van patienten met een tumor met een intakte basaal-
membraan. Er werd geen samenhang gezien met het optreden van recidie-
ven. 
Het selectief meten van kernen (morfometrie) werd gebruikt als een kwanti-
tatieve maat voor kern gradering. Bij WHO graad II tumoren (histologische 
gradering) kon een morfometrische diversiteit worden aangetoond. Er werd 
een verschil gevonden in overleving tussen morfometrisch bepaalde laag- en 
hooggradig kwaadaardige gevallen. De aanwezigheid van grate kernen wees 
op een slechte prognose. Deze morfometrische gradering kon ook de progres-
sie voorspellen. 
Het DNA gehalte van kernen werd bestudeerd met behulp van DNA beeld 
cytometrie. Bij DNA beeld cytometrie wordt het DNA van individuele kernen 
gemeten. Deze methode is gevoeliger om de plo1die vast te ste!len dan flow 
cytometrie, speciaal in gezwellen met een laag aantal aneuplo!de cellen in een 
overmaat van diplo1de cellen. Er werd een significant verschil in overleving 
gevonden tussen DNA beeld cytometrisch vastgestelde diplo1de en niet di-
plo1de gezwellen. De aanwezigheid van een groot aantal cell en met een hoog 
DNA gehalte voorspelde een slechte prognose. Het aantal kernen dat een 
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DNA gehalte had dat afweek van het diploide gehalte (2CDI) bleek eveneens 
een indicator voor overleving. Deze beeld cytometrische factoren bleken 
eveneens progressie te kunnen voorspellen. • 
Wij onderzochten ook het mogelijk nut van numerieke chromosoom afwijkin-
gen in metafase kernen als voorspellende factor van het klinische gedrag van 
blaastumoren. De overleving van patienten met een diploid modaal aantal 
chromosomen was beter dan van patienten met een tumor met een hyperdi-
ploid aantal chromosomen. Progressie werd eveneens meer gezien bij patien-
ten met een hyperdiploid aantal chromosomen. 
De beoordeling van chromosomen in metafase kernen werd vergeleken met 
chromosoom onderzoek met behulp van fluorescentie in situ hybridisatie op 
interfase kernen. Bij deze techniek werden specifieke nucleinezuur "probes" 
voor de chromosomen 1, 7, 9 en 11 gebruikt. Beide methoden vullen elkaar 
aan omdat het klassieke chromosoom onderzoek beter in staat stelt diversiteit 
vast te stellen na tetra- en polyploidisatie, terwijl in situ hybridisatie het 
mogelijk maakt om de betrokkenheid van specifieke chromosomen te bepalen 
bij karyotypische afwijkingen. Het klassieke chromosoom onderzoek lukt 
niet bij aile tumoren, in situ hybridisatie meestal wel. 
Bij het analyseren van combinaties van de verschillende parameters uit ons 
onderzoek bleek het stadium de belangrijkste factor te zijn voor het bepalen 
van de prognose. De rnitosefrequentie bleek een factor die onafhankelijk van 
het stadium, aanvullende informatie geeft voor het voorspellen van progres-
sie. Bij oppervlakkige blaastumoren bleken het modaal aantal chromosomen 
en een van de beeld cytometrische factoren (2CDI) het meest belangrijk voor 
het bepalen van overleving en progressie. Chromosoom onderzoek met be-
hulp van in situ hybridisatie op interfase kernen moet nog verder onderzocht 
worden op zijn klinische bruikbaarheid. 
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DANKWOORD 
Het onderzoek voor dit proefschrift werd voor een belangrijk dee! uitgevoerd 
in het kader van het praeventiefonds project "Preventie van over- en onder-
behandeling van blaastumoren: Ontwikkeling van een prognostische index". 
Het onderzoek heeft plaatsgevonden in het laboratorium voor pathologie van 
de stichting ziekenhuizen Noord-Limburg, Venlo, het klinisch chemisch labo-
ratorium van de stichting ziekenhuis apotheek en laboratorium, Venray, het 
Sylvius laboratorium van de Universiteit van Leiden en de afdeling molecu-
laire biologie van de Universiteit Limburg. Er werd bovendien intensief 
samengewerkt met de vakgroepen Pathologie van de Universiteit van Lim-
burg, Maastricht, en van de Erasmus Universiteit, Rotterdam. 
Het voorbereiden en schrijven van een proefschrift is bijna nooit het product 
van een of enkele personen. Velen hebben dan ook bijgedragen aan het 
totstandkomen van dit boekje, deels zelfs onbewust. Het is dan oak bijna 
ondoenlijk een ieder bij name te noemen. Om te voorkomen dat ik iemand 
vergeet, wil ik allen die mij tot steun zijn geweest bij het verrichten van dit 
werk, hartelijk bedanken. 
Een aantal mensen wil ik loch in het bijzonder noemen. 
In 1978 werd op initiatief van Ruud Pauwels het onderzoek naar blaastumo-
ren gestart in het St. Maartens Gasthuis Venlo. Samen met Wim Smeets 
ontstond een hecht "Urologisch-Genetisch-Pathologisch" pact. 
Ruud en Wim, jullie hebben mij in 1987 onder het genal van een glas wijn, 
gesuggereerd de reeds verrichte inspanningen op het gebied van de blaastu-
moren uit te breiden tot een promotiewaardig onderzoek. 
Jullie enthousiasme en doorzettingsvermogen was voor mij een stimulans om 
het werk aan te vangen en af te ronden. 
Prof. Dr. F.T. Bosman, beste Pre, jij hebt je in december 1987 bereid verklaard 
op te treden als mijn promotor. In je brief van toen toonde je je verheugd over 
het feit dat een perifere patholoog zich weer op het smalle pad van de 
wetenschap durfde begeven. Je gaf aan dat je dit onderzoek wei zag zitten. 
Jou snelle en deskundige adviezen aangaande de inhoud van de afzondelijke 
hoofdstukken en uiteindelijk het hele manuscript waren voor mij van on-
schatbare waarde. 
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De !eden van de beoordelingscommissie dank ik voor de voortvarende wijze 
waarop zij het manuscript hebben getoetst. 
De diverse co-auteurs van de afzondelijke hoofdstukken hadden ieder op hun 
vakgebied gewaardeerde inbreng. 
Piet van den Brandt, afdeling epidemiologie van de Universiteit Limburg, en 
Jack Wijnen, afdeling wiskunde en informatica van de technische Universiteit 
Eindhoven, worden bedankt voor hun hulp bij de statistische bewerking van 
de gegevens. 
Jan Willem Arends en Eric Thunnissen, afdeling Pathologie van de Universi-
teit Limburg en Jan Willem Coebergh, epidemiloog en adviseur van het 
Intergraal Kankercentrum Zuid, dank ik voor hun medewerking en totstand-
koming van hoofdstuk 2. 
Miek Havenith, destijds afdeling pathologie van de Universiteit Limburg, 
tegenwoordig afdeling pathologie Enschede, wi! ik danken voor de inbreng 
van zijn expertise op het gebied van de basaal membranen en voor het tot 
stand komen van hoofdstuk 3. 
Hoofdstuk 5 kwam tot stand in nauwe samenwerking met het Sylvius Labo-
ratorium van de Universiteit Leiden. Joke (Ploem) en Hans (Tanke) jullie inzet 
en enthousiasme voor de Leidse cytometrie was zeer stimulerend. Irma Ou-
werkerk wil ik bedanken voor de technische bewerking van het materiaal in 
Leiden. Zonder jullie hulp was hoofdstuk 5 niet tot stand gekomen. 
De vergelijking van het conventionele chromosoom onderzoek met het ISH 
onderzoek op interfase kernen, zoals beschreven in hoofdstuk 7 kwam tot 
stand in samenwerking met de afdeling moleculaire biologie en genetica van 
de Universiteit Limburg. Ton Hopman, Frans Ramaekers en Joep Geraedts 
worden bedankt voor hun deskundige hulp bij het tot stand komen van dit 
hoofdstuk. 
Rene Retera, mijn associe, bedankt voor je belangstelling en steun bij dit 
onderzoek. Zonder enig probleem werd door jou een dee! van mijn werk 
overgenomen als ik weer eens naar de statisticus, de promotor of andere 
wetenschappers moest. 
Collega Jan Scheepers, Uroloog, wil ik bedanken voor het beschikbaar stellen 
van zijn patientenbestand en voor de nauwgezette follow-up van zijn blaas-
carcinoom pa tienten. 
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Natuurlijk moe! ik ook aile medewerkers van het laboratorium voor Patholo-
gie van de stichting ziekenhuizen Noord Limburg bedanken voor de extra 
inspanningen die geleverd moesten worden voor mijn onderzoek. 
Met name Wies Hamstra wil ik bedanken. Wies jou nauwgezet bewaken van 
het patienten materiaal, de immunohistochemie en het prepareren van het 
materiaal voor image cytometrie waren van groot belang voor het onderzoek. 
Wouter Tiggelovend dank ik voor het meten van vele kemen. Deze meetge-
gevens werden gebruikt in hoofdstuk 4. 
De dames van het secretariaat dank ik voor het tot vervelens opzoeken van 
patientengegevens. 
Jan van de Kerkhof wil ik bedanken voor het tekenen van de grafieken uit de 
diverse hoofdstukken. 
Dank ook aan Anja van Gulick voor het verzorgen van litteratuur gegevens. 
De medewerkers van de afdeling ABC van het St. Maartens Gasthuis dank ik 
voor de vele praktische tips die ik van hen kreeg als ik weer eens even was 
vastgelopen met de PC. 
Sue Muysers-Godfrey dank ik voor het kritisch doorlezen en corrigeren van 
de tekst van het manuscript. 
Het bestuur en de directie van de Stichting Ziekenhuizen Noord-Limburg en 
van de stichting Ziekenhuis en Apotheek Venray, wil ik bedanken voor de 
mogelijkheden die geschapen werden om onderzoek te verrichten in een 
perifeer ziekenhuis. 
Wekenlang werd door Moon elke avond besteed aan het vastleggen van aile 
gegevens van het onderzoek in het patientenbestand op de PC. Hiermee werd 
de basis voor dit proefschrift gelegd. 
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